false
0001857086
0001857086
2023-11-02
2023-11-02
0001857086
DMAQ:ClassCommonStockParValue0.0001PerShareMember
2023-11-02
2023-11-02
0001857086
DMAQ:RightsEachExchangeableIntoOnetenthOfOneShareOfClassCommonStockMember
2023-11-02
2023-11-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 2, 2023
Deep
Medicine Acquisition Corp.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40970 |
|
85-3269086 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
595
Madison Avenue, 12th Floor
New
York, NY |
|
10017 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (917) 289-2776
N/A |
(Former
name or former address, if changed since last report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions:
☒ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Class
A Common Stock, par value $0.0001 per share |
|
DMAQ |
|
The
Nasdaq Stock Market LLC |
|
|
|
|
|
Rights,
each exchangeable into one-tenth of one share of Class A Common Stock |
|
DMAQR |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01. Entry into a Material Definitive Agreement.
Capitalized
terms used in this section but not otherwise defined herein have the same definitions given to such terms in the Transaction Documents.
On
November 2, 2023, Deep Medicine Acquisition Corp., a Delaware corporation (“DMAQ” or the “Company”),
executed a Loan Agreement (together, the “Loan Agreements”) with each of Greentree Financial Group, Inc. and Finuvia,
LLC (together, the “PIPE Investors”). Pursuant to the terms and conditions of the Loan Agreements, DMAQ shall issue
the PIPE Investors up to $8,000,000 in principal amount of convertible notes (the “Convertible
Notes”) and warrants to purchase 727,273 shares of Class A common stock (the “Warrants”, and together with
the Loan Agreements, the Convertible Notes, and the Registration Rights Agreement (as defined below), the “Transaction Documents”)
of the Company after the closing (the “Closing”) of the business combination between DMAQ and TruGolf, Inc., (“TruGolf”)
a Nevada corporation (the “Business Combination”) pursuant to an Agreement and Plan of Merger (the “Merger
Agreement”), which was previously announced by DMAQ on March 31, 2023. Following the Closing, the Company will change its name
to TruGolf, Inc. (“New TruGolf”). The Loan Agreement contemplates funding of the investment (the “Investment”
or the “PIPE”) across three tranches:
|
(i)
|
The
first closing amount of $2,110,000 in the aggregate, will be invested upon the closing of the Business Combination and the satisfaction
of other closing conditions, which will be the first closing date of the Investment (the “First Closing Date”),
in exchange for Convertible Notes to be issued by New TruGolf in the principal amount of $2,400,000 reflecting a 10% original issue
discount to the face amount thereof and $25,000 allowance for each PIPE Investor’s legal fees. Further, all of the Warrants
shall also be issued on the First Closing Date. |
|
|
|
|
(ii)
|
The
second closing amount of $2,160,000, in the aggregate, will be invested within three business days from New TruGolf filing the Registration
Statement (as defined below), which will be the second closing date of the Investment (the “Second Closing Date”),
in exchange for Convertible Notes to be issued by New TruGolf in the principal amounts of $2,400,000, reflecting a 10% original issue
discount to the face amount thereof; provided that all conditions to the PIPE Investors’ and New TruGolf’s obligations
set forth in the Transaction Documents have been satisfied or waived prior to the Second Closing Date, and the respective obligations
to consummate the Second Closing shall be contingent on Stockholder Approval (as defined below) and New TruGolf exercising its discretion
to enter into the to second tranche of the Investment. |
|
|
|
|
(iii)
|
The
third closing amount of $2,880,000, in the aggregate, will be invested within three business days of the Registration Statement being
declared effective, which will be the third closing date of the Investment (the “Third Closing Date”), in exchange
for Convertible Notes to be issued by New TruGolf in the principal amount of $3,200,000, reflecting a 10% original issue discount
to the face amount thereof; provided that all conditions to the PIPE Investors’ and New TruGolf’s obligations set forth
in the Transaction Documents have been satisfied or waived prior to the Third Closing Date, and the respective obligations
to consummate the Third Closing shall be contingent on Stockholder Approval and New TruGolf exercising its discretion to
enter into the to third tranche of the Investment. |
Each
Convertible Note will mature on the date that is five years from each respective closing date (the “Maturity Date”)
and is convertible at any time at the holder’s option at a conversion price of the lower of $10 per share or the lowest of New
TruGolf’s VWAP for the 10 consecutive trading days following the date of the closing of the Business Combination, subject to adjustment
and a floor price of $5.00 per share (the “Conversion Price”). New TruGolf may, at its option, at any time and from
time to time, prepay all or any part of the principal balance of the Convertible Notes before the Maturity Date subject to certain notice
requirements. If New TruGolf or any subsidiary thereof, as applicable, at any time while a Convertible Note is outstanding, shall sell
or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale,
grant or any option to purchase or other disposition) any Class A common stock of New TruGolf (the “Class A Common Stock”)
or securities entitling any person or entity to acquire shares of Class A Common Stock (upon conversion, exercise or otherwise), at an
effective price per share less than the Conversion Price then the Conversion Price shall be reduced at the option of the PIPE Investor
to the same base share price as the new investment.
Additionally,
on each date in which a conversion occurs, New TruGolf shall pay to the PIPE Investors in Class A Common Stock (the “Make-Whole
Shares”) the sum of (A) all accrued interest on the Convertible Notes to date plus (B) all interest that would otherwise accrued
on such principal amount of the Convertible Notes if such converted principal would be held to the Maturity Date (the “Make-Whole
Amount”) at the Interest Conversion Rate (as defined below). However, New TruGolf shall have the ability to elect to pay the
Make-Whole Amount in cash or in Make-Whole Shares at the Interest Conversion Rate if New TruGolf’s Class A Common Stock’s
VWAP is less than $6.00 per share for 5 consecutive trading days ending on the trading day that is immediately prior to the make-whole
payment.
Interest
shall accrue on the aggregate unconverted and then outstanding principal amount of the Convertible Notes at a rate of 10% per annum,
payable quarterly on January 1, April 1, July 1 and October 1. If New TruGolf’s Class A Common Stock’s VWAP is greater than
or equal to $6.00 per share for five consecutive trading days prior to the interest payment date, the PIPE Investor may elect to receive
interest payments in cash, or Class A Common Stock with an effective interest rate of 15% per annum and a conversion rate of 90% of the
lowest VWAP for the 5 consecutive trading days ending on the trading day that is immediately prior to the date on which interest is paid
in Class A Common Stock (adjusted for share splits, share dividends or similar events) (the “Interest Conversion Rate”).
If New TruGolf’s Class A Common Stock’s VWAP is less than $6.00 per share for five consecutive trading days immediately prior
to the interest payment date, New TruGolf may elect to pay the interest payments in cash or Class A Common Stock at the Interest Conversion
Rate, in its sole discretion.
As
additional consideration for the purchase of the Convertible Notes, New TruGolf will issue to the PIPE Investors, on the First Closing
Date, the Warrants to purchase 727,273 shares of Class A Common Stock (such shares, the “Warrant Shares”) at the exercise
price of $13.00 per Warrant Share (the “Exercise Price”). If New TruGolf or any subsidiary thereof, as applicable,
at any time while the Warrants are outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or
otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Class A Common
Stock or securities entitling any person or entity to acquire shares of Class A Common Stock (upon conversion, exercise or otherwise),
at an effective price per share less than the then Exercise Price then the Exercise Price shall be reduced at the option of the PIPE
Investor to the same base share price as the new investment. Further, subject to a floor price of $5.00, as adjusted, the Exercise Price
shall be adjusted to one hundred thirty percent (130%) of the lowest VWAP for the 10 consecutive trading days following the date of the
closing of the Business Combination. The Warrants are exercisable for a period of five years and will be subject to cashless exercise
if on or after 90 days from the Warrants’ issue date, there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the PIPE Investors.
In
compliance with Nasdaq Listing Rule 5635(d), New TruGolf shall not effect the conversion of any of the Class A Common Stock under the
Convertible Notes, or the exercise of the Warrants held by the PIPE Investors, or pay any dividend in the form of common stock, and the
PIPE Investors shall not have the right to convert any of the Class A Common Stock or exercise Warrants held by such PIPE Investor and
any such conversion or exercise shall be null and void and treated as if never made, if to the extent that after giving effect to such
payment of dividend in the form of common stock, or such conversion of the Convertible Note or exercise of such Warrant, the aggregate
outstanding shares of all classes of New TruGolf’s common stock issuable to the PIPE Investors would exceed, when added to the
previously issued shares of Class A Common Stock under the Transaction Documents, the requirements of Nasdaq Listing Rule 5635(d) (“Nasdaq
19.99% Cap”), except that such limitation will not apply at any time following Stockholder Approval. The date in which the
Nasdaq 19.99% Cap is calculated shall be the date immediately preceding the issuance of the securities before the issuance of the Warrants
and Convertible Notes.
Within
sixty days from the closing of the Business Combination, New TruGolf shall use commercially reasonable efforts to hold a special stockholder
meeting seeking stockholder approval of the Investment (the “Stockholder Approval”). If, despite New TruGolf’s
commercially reasonable efforts, the Stockholder Approval is not initially obtained, New TruGolf shall cause an additional stockholder
meeting to be held every three (3) months thereafter until such Stockholder Approval is obtained.
In
conjunction with the Investment, the parties shall enter into a registration rights agreement (the “Registration Rights Agreement”).
In accordance with the terms and conditions of the Registration Rights Agreement, New TruGolf shall prepare and file with the United
States Securities and Exchange Commission (the “Commission” or “SEC”) a registration statement
on Form S-1 or Form S-3 (the “Form S-1”, “Form S-3”, or “Registration Statement”),
to the extent permitted under the applicable law and by the Commission, within 30 days from the Closing of the Business Combination (the
“Filing Date”) to the Class A Common Stock underlying all of the Convertible Notes and Warrants issuable hereunder,
assuming the full conversion of the Convertible Notes into shares of Class A Common Stock and the payment of all interest on the Convertible
Notes in shares of Class A Common Stock at the “floor” price set forth in the Notes and the Warrant. The Registration Statement
must be effective within 75 days from the Filing Date (the “Effectiveness Date”). There shall be monthly liquidated
damages equal to 2.0% of the Principal Amount if (i) the Registration Statement is not filed on or prior to its Filing Date, (ii) a Registration
Statement is not declared effective by the Commission or does not otherwise become effective on or prior to its required Effectiveness
Date and/or (iii) after its effective date, such Registration Statement ceases for any reason to be effective as to all Registrable Securities
(as defined in the Registration Rights Agreement) to which it is required to cover at any time prior to the expiration of the Effectiveness
Period (as defined in the Registration Rights Agreement), which damages shall accrue each month until the applicable breach (failure
to timely file, failure to timely have declared effective, or ceasing to be effective) has been cured.
The
foregoing description of the Transaction Documents does not purport to be complete and is qualified in its entirety by the terms and
conditions of the Transaction Documents, copies of which are attached hereto as Exhibits 4.1, 10.1, 10.2 and 10.3, and are incorporated
herein by reference.
Item
2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.
The
disclosure contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.
Item
3.02. Unregistered Sales of Equity Securities.
The
disclosure contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02. The shares of Class
A Common Stock to be issued to the PIPE Investors will not be registered under the Securities Act in reliance on the exemption from registration
provided by Section 4(a)(2) of the Securities Act thereunder.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
*
The exhibits and schedules to this Exhibit have been omitted in accordance with Item 601(b)(2) of Regulation S-K. The Registrant agrees
to furnish supplementally to the SEC a copy of all omitted exhibits and schedules upon its request.
Important
Information About the Business Combination and Where to Find It
In
connection with the Merger Agreement and the proposed Business Combination, the Company has filed the Registration Statement with the
SEC, which includes a preliminary proxy statement/prospectus, and plans on filing a definitive proxy statement/prospectus with respect
to the solicitation of proxies for the special meeting of stockholders of the Company to vote on the Business Combination (the “Proxy
Statement/Prospectus”). A full description of the terms of the Merger Agreement and business combination is included in the
Registration Statement. The Company urges its investors, stockholders and other interested persons to read, the preliminary Proxy
Statement/Prospectus, and when available, the definitive Proxy Statement/Prospectus as well as other documents filed with the SEC because
these documents will contain important information about the Company, TruGolf and the Business Combination. The definitive Proxy
Statement/Prospectus will be mailed to stockholders of the Company as of a record date to be established for voting on the Business Combination.
Once available, stockholders will also be able to obtain a copy of the definitive Proxy Statement/Prospectus, and other documents filed
with the SEC, without charge, by directing a request to: Deep Medicine Acquisition Corp. 595 Madison Avenue, 12th Floor, New York, NY
10017, (917) 289-2776 or on the SEC’s website at www.sec.gov.
Participants
in the Solicitation
The
Company and TruGolf, and their respective directors and executive officers, may be deemed participants in the solicitation of proxies
of the Company’s stockholders in respect of the proposed Business Combination. The Company’s stockholders and other interested
persons may obtain more detailed information about the names and interests of these directors and officers of the Company and TruGolf
in the Business Combination will be set forth in filings with the SEC, including when filed, the definitive Proxy Statement/Prospectus.
These documents can be obtained free of charge from the sources specified above and at the SEC’s web site at www.sec.gov.
Forward-Looking
Statements
This
Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995 with respect to the proposed Business Combination. These forward-looking
statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,”
“estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,”
“may,” “should,” “will,” “would,” “will be,” “will continue,”
“will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations
and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates
and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors
could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited
to: (i) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price
of DMAQ’s securities; (ii) the failure to satisfy the conditions to the consummation of the Business Combination, including the
approval of the Merger Agreement by the stockholders of DMAQ; (iii) the occurrence of any event, change or other circumstance that could
give rise to the termination of the Merger Agreement; (iv) the outcome of any legal proceedings that may be instituted against any of
the parties to the Merger Agreement following the announcement of the entry into the Merger Agreement and proposed Business Combination;
(v) the ability of the parties to recognize the benefits of the Merger Agreement and the Business Combination; (vi) the lack of useful
financial information for an accurate estimate of future capital expenditures and future revenue (vii) statements regarding TruGolf’s
industry and market size, (viii) financial condition and performance of TruGolf, including the anticipated benefits, the implied enterprise
value, the expected financial impacts of the Business Combination, potential level of redemptions of DMAQ’s public stockholders,
the financial condition, liquidity, results of operations, the products, the expected future performance and market opportunities of
TruGolf, and (ix) those factors discussed in DMAQ’s filings with the SEC and that that will be contained in the definitive proxy
statement / prospectus relating to the Business Combination. You should carefully consider the foregoing factors and the other risks
and uncertainties that will be described in the “Risk Factors” section of the definitive proxy statement / prospectus and
other documents to be filed by DMAQ from time to time with the SEC. These filings identify and address other important risks and uncertainties
that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and
while TruGolf and DMAQ may elect to update these forward-looking statements at some point in the future, they assume no obligation to
update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, subject to applicable
law. Neither of TruGolf or DMAQ gives any assurance that TruGolf or DMAQ, or the combined company, will achieve its expectations.
No
Offer or Solicitation
This
Current Report on Form 8-K will not constitute a solicitation of a proxy, consent or authorization with respect to any securities or
in respect of the business combination. This Current Report on Form 8-K will also not constitute an offer to sell or the solicitation
of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities
will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, as amended, or an exemption
therefrom.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Deep
Medicine Acquisition Corp. |
|
|
|
Date:
November 2, 2023 |
By: |
/s/
Humphrey P. Polanen |
|
Name: |
Humphrey
P. Polanen |
|
Title: |
Chief
Executive Officer |
Exhibit
4.1
Exhibit
B
NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER AND REASONABLY APPROVED BY THE COMPANY),
IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A
UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
COMMON
STOCK PURCHASE WARRANT
Number
of shares: |
Holder:
|
|
|
Exercise
Price per Share: $13.00 |
Warrant
No.: |
|
|
Expiration
Date: _______1 , 2028 |
Issue
Date: _________ , 2023 |
FOR
VALUE RECEIVED, TruGolf Inc., a Delaware corporation (the “Company”), hereby certifies that , or
its designated assigns (the “Warrant Holder”), is entitled to purchase the securities set forth below.
This
Warrant entitles the Warrant Holder to purchase from the Company at any time after the Issue Date and before the Expiration Date shares
(the “Warrant Shares”) of Class A Common Stock (the “Common Stock”) of the Company at an exercise
price of $13.00 per share (as adjusted from time to time as provided in Section 7 hereof, the “Exercise Price”),
at any time and from time to time from and after the Issue Date and through and including 5:00 p.m. New York time on the Expiration Date.
This
Warrant is being issued pursuant to that certain Loan Agreement, dated as of November 2, 2023 by and between the Company and the
Warrant Holder, (the “Loan Agreement”). Capitalized terms used herein but not otherwise defined herein, shall have the meanings
given to them in the Loan Agreement.
1
Expiration Date shall be 5 years from the Issue Date
This
Warrant is subject to the following terms and conditions:
1.
Registration of Warrant. The Company shall register this Warrant upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Warrant Holder hereof from time to time. The Company may deem
and treat the registered Warrant Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Warrant Holder, and for all other purposes, unless provided notice to the contrary in accordance herewith.
2.
Investment Representation. The Warrant Holder by accepting this Warrant represents that the Warrant Holder is acquiring this Warrant
for its own account or the account of an affiliate for investment purposes and not with the view to any offering or distribution and
that the Warrant Holder will not sell or otherwise dispose of this Warrant or the underlying Warrant Shares in violation of applicable
securities laws. The Warrant Holder acknowledges, until such time that the Warrants are registered in accordance with Section 8 of this
Warrant, that the certificates representing any Warrant Shares will bear a legend indicating that they have not been registered under
the United States Securities Act of 1933, as amended (the “1933 Act”) and may not be sold by the Warrant Holder except
pursuant to an effective registration statement or pursuant to an exemption from registration requirements of the 1933 Act and in accordance
with federal and state securities laws. If this Warrant was acquired by the Warrant Holder pursuant to the exemption from the registration
requirements of the 1933 Act afforded by Regulation S thereunder, the Warrant Holder acknowledges and covenants that this Warrant may
not be exercised by or on behalf of a Person during the one-year distribution compliance period (as defined in Regulation S) following
the date hereof. “Person” means an individual, partnership, firm, limited liability company, trust, joint venture,
association, corporation, or any other legal entity.
3.
Validity of Warrant and Issue of Shares. The Company represents and warrants that this Warrant has been duly authorized and validly
issued and warrants and agrees that all of Warrant Shares that may be issued upon the due exercise of the rights represented by this
Warrant will, when issued upon such exercise, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges with respect to the issue thereof. The Company further warrants and agrees that during the period within which the
rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved a sufficient number of
shares of Common Stock to provide for the exercise of the rights represented by this Warrant which shall be evidenced by the Company
in the TA Instruction Letter in accordance with the terms and conditions in the Loan Agreement.
4.
Registration of Transfers and Exchange of Warrants.
a.
Subject to compliance with the legend set forth on the face of this Warrant, the Company shall register the transfer of this Warrant,
or any portion of this Warrant, in the Warrant Register, upon delivery by the Warrant Holder to the Company, pursuant to Section 12 of
(i) this Warrant, and (ii) a duly completed and executed written assignment. Upon any such registration or transfer, a new warrant to
purchase Common Stock, in substantially the form of this Warrant (any such new warrant, a “New Warrant”), evidencing
the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this
Warrant not so transferred, if any, shall be issued to the transferring Warrant Holder. The acceptance of the New Warrant by the transferee
thereof shall be deemed the acceptance of such transferee of all of the rights and obligations of a Warrant Holder of a Warrant.
b.
This Warrant is exchangeable, upon the surrender hereof by the Warrant Holder to the office of the Company specified in or pursuant to
Section 12 for one or more New Warrants, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then
be purchased hereunder. Any such New Warrant will be dated the date of such exchange, and will have the same Expiration Date as the original
Warrant for which the New Warrant was exchanged.
5.
Exercise of Warrants.
a.
Exercise of this Warrant shall be made upon delivery to the Company pursuant to Section 12, of (i) this Warrant; (ii) a duly completed
and executed election notice, in the form attached hereto (the “Election Notice”) and (iii) payment of the Exercise Price.
Payment of the Exercise Price may be made at the option of the Warrant Holder either (a) in cash, wire transfer or by certified or official
bank check payable to the order of the Company equal to Exercise Price per share in effect at the time of exercise multiplied by the
number of Warrant Shares specified in the Election Notice, or (b) through a cashless exercise provided in Section 5(b) below. The Company
shall promptly (but in no event later than three (3) business days after the “Date of Exercise,” as defined herein) issue
or cause to be issued and cause to be delivered to the Warrant Holder in such name or names as the Warrant Holder may designate in the
Election Notice, a certificate for the Warrant Shares issuable upon such exercise, with such restrictive legend as required by the 1933
Act, as applicable. Any person so designated by the Warrant Holder to receive Warrant Shares shall be deemed to have become holder of
record of such Warrant Shares as of the Date of Exercise of this Warrant. All Warrant Shares delivered to the Warrant Holder the Company
covenants, shall upon due exercise of this Warrant, be duly authorized, validly issued, fully paid and non-assessable.
b.
If at the time of exercise hereof, on or after the date that is ninety (90) days immediately following the Issue Date there is no effective
registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the
Holder and if the closing price per share of the Common Stock (as quoted by the Nasdaq Global Market or other principal trading market,
if applicable) reported on the day immediately preceding the Date of Exercise (the “Fair Market Value”) of one share
of the Common Stock is greater than the Exercise Price of one Warrant Share (at the date of calculation as set forth below), in lieu
of exercising this Warrant for cash, the Warrant Holder may elect to receive that number of Warrant Shares computed using the following
formula:
Where
X= the number of shares of Common Stock to be issued to the Warrant Holder
Y=
the number of shares of Warrant Shares purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion
of this Warrant being exercised (at the date of such calculation)
A=
Fair Market Value
B=
Exercise Price (as adjusted to the date of such calculation)
For
purposes of Rule 144 promulgated under the 1933 Act, it is intended, understood and acknowledged that the Warrant Shares issued in a
cashless exercise transaction in the manner described above shall be deemed to have been acquired by the Warrant Holder, and the holding
period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued.
c.
A “Date of Exercise” means the date on which the Company shall have received (i) this Warrant (or any New Warrant,
as applicable), (ii) the Election Notice (or attached to such New Warrant) appropriately completed and duly signed, and (iii) payment
of the Exercise Price (if this Warrant is exercised on a cash basis) for the number of Warrant Shares so indicated by the Warrant Holder
to be purchased.
d.
If at any time the VWAP of the Common Stock on the principal market exceeds $15.00 (as adjusted for stock splits, stock dividends, stock
combinations, recapitalizations and similar events) (the “Forced Exercise Minimum Price”) for ten consecutive Trading Days
(each, a “Forced Exercised Measuring Period”), the Company shall have the right to require the Warrant Holder to exercise
the Warrant pursuant to this Warrant Agreement into and up to such aggregate number of fully paid, validly issued and non-assessable
Warrant Shares reach the beneficial ownership restrictions in this Section 5 (each a “Forced Exercise”). Notwithstanding
the foregoing, the Company may not exercise its right to require the Forced Exercise unless it has fulfilled its obligations under Section
8 of this Warrant Agreement and the terms of the Registration Rights Agreement. The Company may exercise its right to require the Forced
Exercise under this Section 5(d) on the Trading Day immediately following the Forced Exercise Measuring Period by delivering written
notice thereof, by electronic mail to the Warrant Holder by no later than 9:30 AM, New York City time.
e.
This Warrant shall be exercisable at any time and from time to time for such number of Warrant Shares as is indicated in the attached
Form of Election to Purchase. If less than all of the Warrant Shares which may be purchased under this Warrant are exercised at any time,
the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of
Warrant Shares for which no exercise has been evidenced by this Warrant.
f.
Notwithstanding any other provision of this Warrant, the Warrant Holder may not exercise this Warrant if such exercise would cause (i)
Warrant Holder’s beneficial ownership (as defined by Section 13(d) of the Securities Exchange Act of 1934, as amended) of the Common
Stock of the Company to exceed 9.99% of its total issued and outstanding Common Stock or voting shares, or (ii) Warrant Holder to exceed
the Nasdaq 19.99% Cap, without Shareholder Approval.
6.
Reserved.
7.
Adjustment of Exercise Price and Number of Shares. The character of the shares of stock or other securities at the time issuable
upon exercise of this Warrant and the Exercise Price therefor, are subject to adjustment upon the occurrence of the following events:
a.
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company
with or into another entity and the Company is not the surviving entity (such surviving entity, the “Successor Entity”),
(ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any tender
offer or exchange offer (whether by the Company or by another individual or entity, and approved by the Company) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash or property
and the holders of at least 50% of the Common Stock accept such offer, or (iv) the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property (other than as a result of a subdivision or combination of shares of Common Stock) (in any such case, a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive the number of
shares of Common Stock of the Successor Entity or of the Company and any additional consideration (the “Alternate Consideration”)
receivable upon or as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of
the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding any limitation
on exercise contained herein solely for the purpose of such determination). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any Successor Entity in such Fundamental Transaction
shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to exercise
such warrant into Alternate Consideration.
b.
Anti-Dilution Adjustments to Exercise Price. If the Company or any subsidiary thereof, as applicable, at any time while this Warrant
is outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or
announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or securities entitling any person or
entity to acquire shares of Common Stock (upon conversion, exercise or otherwise) (including but not limited to under the Note), at an
effective price per share less than the then Exercise Price (such lower price, the “Base Share Price” and such issuances
collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any
time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise,
or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common
Stock at an effective price per share which is less than the Exercise Price, such issuance shall be deemed to have occurred for less
than the Exercise Price on such date of the Dilutive Issuance), then the Exercise Price shall be reduced at the option of the Holder
and only reduced to equal the Base Share Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents
are issued. The Company shall notify the Holder in writing, no later than two (2) Trading Days following the issuance of any Common Stock
or Common Stock Equivalents subject to this Section 7(b), indicating therein the applicable issuance price, or applicable reset price,
exchange price, conversion price and other pricing terms (such notice the “Dilutive Issuance Notice”). For purposes of clarification,
whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 7(b), upon the occurrence of any Dilutive Issuance,
after the date of such Dilutive Issuance the Holder is entitled to receive a number of Warrant Shares based upon the Base Share Price
regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise. The foregoing shall not apply to
any Exempt Issuance as defined in the Note.
c.
Exercise Price Adjustment for Trading Price. Subject to a floor price of $5.00 (adjusted in accordance with Section 7(d) of this
Warrant), the Exercise Price shall be adjusted to one hundred thirty percent (130%) of the lowest VWAP for the 10 consecutive Trading
Days following the date of the closing of that certain business combination with TruGolf Inc. (adjusted for shares splits share dividends
and similar events described in Section 7(d) below). “Trading Day” means a day on which the principal trading market is open
for trading. VWAP means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
are then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock are then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Issuer, the fees and expenses of which shall be split by the Issuer and the Purchasers.
d.
Adjustments for Stock Dividends; Combinations, Etc. In case the Company shall do any of the following (an “Event”):
(i)
declare a dividend or other distribution on its Common Stock payable in Common Stock of the Company,
(ii)
subdivide the outstanding Common Stock pursuant to a stock split or otherwise, or
(iii)
reclassify its Common Stock,
then
the number of shares of Common Stock or other securities at the time issuable upon exercise of this Warrant shall be appropriately adjusted
to reflect any such Event.
e.
Certificate as to Adjustments. In case of any adjustment or readjustment in the price or kind of securities issuable on the exercise
of this Warrant, the Company will promptly give written notice thereof to the holder of this Warrant in the form of a certificate, certified
and confirmed by the Board of Directors of the Company, setting forth such adjustment or readjustment and showing in reasonable detail
the facts upon which such adjustment or readjustment is based.
8.
Registration Rights. In accordance with the terms and conditions of the Loan Agreement, the Company and the Holder shall execute
a registration rights agreement.
9.
Fractional Shares. The Company shall not be required to issue or cause to be issued fractional Warrant Shares on the exercise
of this Warrant. The number of full Warrant Shares that shall be issuable upon the exercise of this Warrant shall be computed on the
basis of the aggregate number of Warrants Shares purchasable on exercise of this Warrant so presented. If any fraction of a Warrant Share
would, except for the provisions of this Section 8, be issuable on the exercise of this Warrant, the Company shall, at its option, (i)
pay an amount in cash equal to the Exercise Price multiplied by such fraction or (ii) round the number of Warrant Shares issuable, up
to the next whole number.
10
.. Non-Circumvention. The Company covenants and agrees that it will not, by amendment of its certificate of incorporation, bylaws
or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities,
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at
all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of
the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common
Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be
necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of Common Stock
upon the exercise of this Warrant, and (iii) shall, for so long as this Warrant is outstanding, have authorized and reserved, free from
preemptive rights, ten times the number of shares of Common Stock that is actually issuable upon full exercise of the Warrant (based
on the Exercise Price in effect from time to time, and without regard to any limitations on exercise).
11.
Warrant Holder Not Deemed a Stockholder. Except as otherwise specifically provided herein, this Warrant, in and of itself, shall
not entitle the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained in this Warrant
shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise)
or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.
12.
Notice. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given
in accordance with the notice provisions contained in the Loan Agreement. The Company shall provide the Holder with prompt written notice
(i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment and
(ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution
upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any stock or other securities directly or indirectly
convertible into or exercisable or exchangeable for shares of Common Stock or other property, pro rata to the holders of shares of Common
Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each
case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.
All notices and other communications hereunder shall be in writing and shall be deemed to have been given (i) on the date they are (a)
delivered if delivered in person or (b) sent, if sent by email; (ii) on the date initially received if delivered by facsimile transmission
followed by registered or certified mail confirmation; (iii) on the date delivered by an overnight courier service; or (iv) on the third
business day after it is mailed by registered or certified mail, return receipt requested with postage and other fees prepaid as follows:
|
TruGolf,
Inc. |
|
60
N 1400 W |
|
Centerville,
UT 84014 |
|
Email:
b@trugolf.com |
|
Attn:
Brenner Adams |
|
If
to the Warrant Holder: |
13.
Miscellaneous.
a.
This Warrants is being granted pursuant to the terms of that certain Loan Agreement, dated as of November 2, 2023 by and between
the Company and the Warrant Holder (the “Loan Agreement”). If not otherwise defined herein, all capitalized terms herein
shall have the meanings given to them in the Loan Agreement. Further, all of the terms, representations, warranties, agreements, covenants
and conditions set forth in the Loan Agreement are incorporated herein by reference. To the extent that there is a conflict between any
condition, term or provision of this Warrant and the Loan Agreement, the conditions, terms, and provisions set forth herein shall specifically
supersede the conflicting conditions, provisions and/or terms in the Loan Agreement.
b.
This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and permitted assigns.
This Warrant may be amended only in writing and signed by the Company and the Warrant Holder. Holder may assign this Warrant without
consent from the Company but in accordance with the restrictions herein.
c.
Nothing in this Warrant shall be construed to give to any person or corporation other than the Company and the Warrant Holder any legal
or equitable right, remedy or cause of action under this Warrant; this Warrant shall be for the sole and exclusive benefit of the Company
and the Warrant Holder.
d.
This Warrant shall be governed by, construed and enforced in accordance with the internal laws of the State of Florida without regard
to the principles of conflicts of law thereof.
e.
Each of the parties to this Agreement irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction
of the courts of the State of Florida and of the United States District Court of the Southern District of Florida, and any appellate
court from any thereof, in any action or proceeding arising out of or relating to this Warrant, or for the recognition or enforcement
of any judgment, and each of the parties hereto irrevocably and unconditionally agrees that all claims in respect of any such action
or proceeding may be heard and determined in such Florida State court or, to the fullest extent permitted by applicable law, in such
federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be
enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
f.
The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.
g.
In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonably substitute therefore, and upon
so agreeing, shall incorporate such substitute provision in this Warrant.
h.
The Warrant Holder shall not, by virtue hereof, be entitled to any voting or other rights of a shareholder of the Company, either at
law or equity, and the rights of the Warrant Holder are limited to those expressed in this Warrant.
IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by the authorized officer as of the date first above stated.
|
TruGolf,
Inc. |
|
|
|
|
By: |
|
|
Name: |
|
|
Title:
|
|
Acknowledged
and Agreed: |
|
|
|
|
By:
|
|
|
Name:
|
|
|
Title:
|
|
|
FORM
OF ELECTION TO PURCHASE
(To
be executed by the Warrant Holder to exercise the right to purchase shares of Common Stock under the foregoing Warrant)
To:
The
undersigned, pursuant to the provisions set forth in the attached Warrant, hereby irrevocably elects to purchase (check applicable box):
☐ |
________
shares of the Common Stock covered by such Warrant; or |
|
|
☐ |
the
maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth therein. |
The
undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant, which
is $___________. Such payment takes the form of (check applicable box or boxes):
☐ |
$__________
in lawful money of the United States; and/or |
|
|
☐ |
the
cancellation of such portion of the attached Warrant as is exercisable for a total of _______ shares of Common Stock (using a Fair
Market Value of $_______ per share for purposes of this calculation); and/or |
|
|
☐ |
the
cancellation of such number of shares of Common Stock as is necessary, in accordance with the formula set forth in Section 5 of the
Warrant, to exercise this Warrant with respect to the maximum number of shares of Common Stock purchasable pursuant to the cashless
exercise procedure set forth in Section 5. |
After
application of the cashless exercise feature as described above, _____________ shares of Common Stock are required to be delivered pursuant
to the instructions below.
The
undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within
Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities
Act”), or pursuant to an exemption from registration under the Securities Act.
|
Name
of Warrant Holder: |
|
|
|
(Print)___________________________________________ |
|
(By:)____________________________________________ |
|
(Name:)__________________________________________ |
|
(Title:)__________________________________________ |
|
Signatures
must conform in all respects to the name of the Warrant Holder on the face of the Warrant. |
Exhibit
10.1
Loan
Agreement
LOAN
AGREEMENT
This
Loan Agreement (“Agreement”) is made and entered into in this 2nd day of November 2023 (“Effective Date”),
by and between Deep Medicine Acquisition Corp., a Delaware corporation, its successors and assigns (the “Company” and before
the closing of the Business Combination, the “SPAC”), and Greentree Financial Group, Inc., a Florida corporation (the “Lender”).
RECITALS
WHEREAS,
the Company entered into an Amended and Restated Agreement and Plan of Merger (as may be amended from time to time, the “Merger
Agreement”) with DMAC Merger Sub Inc., a Nevada corporation and newly formed wholly-owned subsidiary of the Company (“Merger
Sub”), Bright Vision Sponsor LLC, a Delaware limited liability company, solely in the capacity as the representative from and after
the effective time of the Merger (as defined in the Restated Merger Agreement) (the “Effective Time”) for the stockholders
of the Company (other than the TruGolf stockholders) (the “Purchaser Representative”), TruGolf, Inc., a Nevada corporation
(“TruGolf”) and Christopher Jones, an individual, solely in his capacity as the representative from and after the Effective
Time for the TruGolf stockholders (the “Seller Representative”);
WHEREAS,
subject to the terms and conditions set forth in the Merger Agreement, upon the consummation of the transactions contemplated thereby,
Merger Sub will merge with and into TruGolf, with TruGolf surviving as a wholly-owned subsidiary of the Company (the “Business
Combination”), and with TruGolf’s equity holders receiving shares of the Company’s common stock;
WHEREAS,
the Company desires working capital and the Lender has agreed to provide up to Five Million Five Hundred Thousand Dollars ($5,500,000.00)
of such capital following the closing of the Business Combination and according to the terms hereof;
WHEREAS,
the Lender and Company are entering into this Agreement to establish terms by which the Lender shall fund the Loans, as set forth herein
and therein the related Note, described below, and the Company shall issue warrants as set forth herein and therein the related Warrant,
described below; and
WHEREAS,
simultaneously the Lender and the Company are entering into that certain Registration Rights Agreement, described below.
AGREEMENT
NOW,
THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the sufficiency
of which is acknowledged by the Lender and Company (each “party” and, collectively, “parties”), the parties hereby
agree as follows:
1.
LOANS; PROMISSORY NOTE. The Lender shall loan the Company up to Five Million Five Hundred Thousand Dollars $5,500,000 (the
“Principal Amount”) with a 10% original issuance discount, pursuant to the terms hereof; provided, nothing herein or otherwise
shall obligate Lender to make any future loans to the Company. All sums advanced pursuant to the terms of this Agreement (a “Loan”)
shall be evidenced by a separate convertible promissory note (each a “Note”), in substantially the form set forth as Exhibit
A hereto. The Note shall be convertible into shares of the Company’s Class A common stock (the “Class A Common Stock”)
pursuant to the terms contained in the Note. All covenants, conditions and agreements contained herein are made a part of the Note, unless
modified therein.
a.
Unless stated otherwise in the Note, the Note will automatically mature five (5) years from the effective date of each applicable Note
(such date, the “Maturity Date”).
b.
All sums advanced pursuant to this Agreement shall bear interest as set forth in Section 2 of the Note.
2.
WARRANTS. On the First Closing Date (as defined below), the Company shall simultaneously issue to the Lender, a warrant in
substantially the form annexed hereto as Exhibit B (the “Warrant”) to purchase an aggregate of Five Hundred Thousand (500,000)
shares of Class A Common Stock (the “Warrant Shares”) at an initial exercise price of Thirteen Dollars ($13.00) per share
(the “Exercise Price”).
3.
PREPAYMENT. The Company may, at its option, at any time and from time to time, prepay all or any part of the principal balance
of the Note before the Maturity Date as set forth in the Note, without any penalty, subject to notice requirements in the Note. In the
event of prepayment, the Lender shall retain the Warrants. Notwithstanding the foregoing, the Company shall provide ten (10) day written
notice, in accordance with Section 18, if it intends to prepay all or any part of the principal balance of this Note before the Maturity
Date during the first six (6) months following the Closing Date of each respective Note.
4.
CLOSING. Each respective closing date shall be on such date in which this Agreement is duly executed
and the closing conditions of this Section 4 have been satisfied or otherwise waived by the Lender or Company, respectfully (each, a
“Closing Date” and collectively, the “Closing Dates”).
1) |
The
obligation of Lender to fund the First Tranche (as defined below) hereunder shall be subject to the following conditions precedent,
each in form and substance reasonably satisfactory to, and to the satisfaction of, the Lender (the “First Closing Date”): |
|
a) |
the
representations and warranties contained in the Transaction Documents (as defined below) are true and correct in all material respects
as of the issue date of the Note(s), both before and after giving effect to the transactions contemplated by the Transaction Documents; |
|
b) |
no
Event of Default shall have occurred and is continuing or would occur as a result of the Transaction Documents; |
|
c) |
receipt
by the Lender of the duly executed Agreement; |
|
d) |
receipt
by the Lender of the executed copies of the Note; |
|
e) |
receipt
by the Lender of executed copies of the Warrants; |
|
f) |
receipt
of the Lender of the duly executed Registration Rights Agreement; |
|
g) |
the
closing of the Business Combination; |
|
h) |
the
Company being listed on the Nasdaq Capital Market or the Nasdaq Global Market after the closing of the Business Combination; and |
|
i) |
the
Company’s transfer agent’s confirmation of receipt of the TA Instruction Letter. |
2) |
The
obligation of Lender to fund the Second Tranche (as defined below) hereunder shall be subject to the following conditions precedent,
each in form and substance reasonably satisfactory to, and to the satisfaction of, the Lender (the “Second Closing Date”): |
|
a) |
the
satisfaction of the conditions precedent in Section 4(1); |
|
b) |
Shareholder
Approval of the Transaction Documents; and |
|
c) |
the
Company exercising its discretion in accordance with Section 6 of this Agreement. |
3) |
The
obligation of Lender to fund the Third Tranche hereunder shall be subject to the following conditions precedent, each in form and
substance reasonably satisfactory to, and to the satisfaction of, the Lender (the “Final Closing Date”): |
|
a) |
the
satisfaction of the conditions precedent in Section 4(1); |
|
b) |
Shareholder
Approval of the Transaction Documents; and |
|
c) |
the
Company exercising its discretion in accordance with Section 6 of this Agreement. |
5.
ALLOWANCE FOR LEGAL FEE. There will be a $25,000 allowance for Lender’s legal fees paid by the Company and deducted
from Lender’s payment, payable as set forth in Section 6 below.
6.
PAYMENT TERMS. Upon satisfaction of the conditions set forth in Section 4 hereof, the signing
of this Agreement and the receipt of a Note in principal amount of $1,650,000, the Lender will pay the Company $1,460,000, net of original
issuance discount and the allowance for legal fees specified in Section 5 hereof (the “First Tranche”). At the Company’s
discretion, within three (3) business days after the filing of the Registration Statement (as defined below), upon satisfaction of the
conditions set forth in Section 4 hereof and the receipt of a Note in principal amount of $1,650,000, the Lender will pay the Company
$1,485,000, net of original issuance discount (the “Second Tranche”). At the Company’s discretion, within three (3)
business days after the Registration Statement is effective, upon satisfaction of the conditions set forth in Section 4 hereof and the
receipt of a Note in principal amount of $2,200,000, the Lender will pay the Company $1,980,000, net of original issuance discount (the
“Third Tranche”). Until such time that the Company files the Registration Statement and it is declared effective, Lender
shall have no obligation to fund the Second Tranche or the Third Tranche, respectively. Should the Company exercise its discretion and
opt to forgo receiving Second Tranche or Third Tranche, it shall provide the Lender written notice in accordance with Section 18 no less
than three (3) business days prior to the filing and effectiveness of the Registration Statement. Further, if the Company fails to meet
its obligations to file Registration Statement and have it declared effective in accordance with Section 7 of this Agreement and the
Registration Rights Agreement, and the terms and conditions of the Note and Warrant, it shall be subject to the Liquidated Damages Penalty.
7.
REGISTRATION RIGHTS. Simultaneously to the Agreement, the Company and the Lender shall execute a registration rights agreement
in substantially the form annexed hereto as Exhibit C (the “Registration Rights Agreement”). In accordance with the
terms and conditions of the Registration Rights Agreement, the Company shall prepare and file with the United States Securities and Exchange
Commission (the “Commission” or “SEC”) a registration statement on Form S-1 or Form S-3 (the “Form S-1”,
“Form S-3”, or “Registration Statement”), to the extent permitted under the applicable law and by the Commission,
within 30 days from the closing of the Business Combination (the “Filing Date”) to the Class A Common Stock underlying all
of the Notes and Warrants issuable hereunder, assuming the full conversion of the Notes into shares of Class A Common Stock and the payment
of all interest on the Notes in shares of Class A Common Stock at the “floor” price set forth in the Notes and the Warrant.
The Registration Statement must be effective within 75 days from the Filing Date (the “Effectiveness Date”). There shall
be monthly liquidated damages equal to 2.0% of the Principal Amount (the “Liquidated Damage Penalty”) if (i) the Registration
Statement is not filed on or prior to its Filing Date, (ii) a Registration Statement is not declared effective by the Commission or does
not otherwise become effective on or prior to its required Effectiveness Date and/or (iii) after its effective date, such Registration
Statement ceases for any reason to be effective as to all Registrable Securities (as defined in the Registration Rights Agreement) to
which it is required to cover at any time prior to the expiration of the Effectiveness Period (any such failure or breach being referred
to as a “Registration Default”), which damages shall accrue each month until the applicable breach (failure to timely file,
failure to timely have declared effective, or ceasing to be effective) has been cured. Notwithstanding anything herein and for the avoidance
of doubt, there shall not be a Registration Default if, and to the extent that such Registration Statement is not permitted under applicable
law or by the Commission. The parties acknowledge and agree that damages which will result to Lender for Company’s failure to timely
file or have declared effective the Registration Statement shall be extremely difficult or impossible to establish or prove, and agree
that the payment of Liquidated Damage Penalty is a reasonable estimate of potential damages and shall constitute liquidated damages for
any breach of this paragraph. Any amounts due under this Section shall be paid by the fifth (5th) day of the month following the month
in which they accrued or, at the option of Lender, added to the principal of the Note. The legal fees associated with filing the Registration
Statement shall be paid by Company.
8.
SHAREHOLDER APPROVAL. Within sixty (60) days from the closing of the Business Combination, the Company shall use commercially
reasonable efforts to hold a special shareholder meeting seeking shareholder approval of the Transaction Documents (the “Shareholder
Approval”). If, despite the Company’s commercially reasonable efforts, the Shareholder Approval is not initially obtained,
the Company shall cause an additional shareholder meeting to be held every three (3) months thereafter until such Shareholder Approval
is obtained. Notwithstanding anything to the contrary contained in this Section 8, the Company shall have no obligation to solicit or
obtain the Shareholder Approval if Nasdaq Listing Rule 5635(d) no longer applies to the Company or would not prohibit the Lender from
acquiring shares of Class A Common Stock pursuant to Note or Warrant without receipt of such Shareholder Approval.
9.
REPRESENTATIONS AND WARRANTIES BY THE COMPANY. In order to induce Lender to enter into this Agreement and to make the Loans
provided for herein, Company represents and warrants to Lender as follows:
a.
Organization, Good Standing and Power. The Company is a corporation duly incorporated, validly existing and in good standing under
the laws of the Delaware and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its
business as it is now being conducted.
b.
Reserved.
c.
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and perform this Agreement,
the Note, the Warrants, and the Registration Rights Agreement (all such documents together with all amendments, schedules, exhibits,
annexes, supplements and related items, to each such document shall hereinafter be collectively referred to as, the “Transaction
Documents”). The execution, delivery and performance of the Transaction Documents by the Company, and the consummation by it of
the transactions contemplated in, have been duly and validly authorized by all necessary corporate action, including a vote of the shareholders,
if so required. The Transaction Documents, when executed and delivered, will constitute valid and binding obligations of the Company
enforceable against the Company in accordance with their terms, except as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally
the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.
d.
Disclosure. None of the Transaction Documents nor any other document, certificate or instrument furnished to the Lender by or
on behalf of the Company in connection with the transactions contemplated by the Transaction Documents contains any untrue statement
of a material fact or omits to state a material fact necessary in order to make the statements made herein or therein, in the light of
the circumstances under which they were made herein or therein, not misleading.
e.
Adequate Shares; Transfer Agent Instructions. The Company will at all times have authorized and reserved a sufficient number of
shares of Common Stock to provide for the exercise of the rights represented by the respective Warrants and Notes. The Company shall
issue irrevocable instructions to the transfer agent in a form acceptable to the Lender (the “TA Instructions Letter”) to
issue certificates or credit shares to the applicable balance accounts at The Depository Trust Company (“DTC”), registered
in the name of the Lender or its respective nominee(s), for the underlying shares for the Note and Warrants in such amounts as specified
from time to time by the Lender to the Company upon conversion of the Notes or exercise of the Warrants in substantially the form attached
as Exhibit D. The Company represents and warrants that no instruction other than the TA Instructions Letter referred to in this
Section will be given by the Company to its transfer agent with respect to the securities, and that the securities shall otherwise be
freely transferable on the books and records of the Company, as applicable, to the extent provided in this Agreement and the other Transaction
Documents. In the event that such sale, assignment or transfer involves the underlying shares sold, assigned or transferred pursuant
to an effective registration statement or in compliance with Rule 144, the Company shall cause its transfer agent to issue such shares
to such buyer, assignee or transferee (as the case may be) without any restrictive legend in accordance with this Agreement to the extent
permitted by applicable law. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to
Lender. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section be inadequate
and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section, that Lender shall be entitled,
in addition to all other available remedies, to seek an order and/or injunction restraining any breach and requiring immediate issuance
and transfer, without the necessity of showing economic loss and without any bond or other security being required. The Company shall
cause its counsel to issue the legal opinion referred to in the TA Instructions Letter to the Company’s transfer agent from and
after the Applicable Date to the extent permissible by law. Any fees (with respect to the transfer agent, counsel to the Company or otherwise)
associated with the issuance of such opinion or the removal of any legends on any of the securities shall be borne by the Company. “Applicable
Date” means the first date on which all of the underlying securities are eligible to be resold by the Lender pursuant to Rule 144
or an effective registration statement.
f.
Periodic Filings. The Company has filed all reports, schedules, forms, statements and other
documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file
such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the “SEC Reports”) on a timely basis or has received a
valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.
Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (“GAAP”), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments. The Company at all times will remain current in its reporting requirements
with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and to maintain its continued listing
of the Company’s Class A Common Stock on Nasdaq Capital Market or the Nasdaq Global Market, as determined by the Company.
g.
Subsequent Equity Sales. Except for the transaction contemplated by the Transaction Documents and any other transactions previously
disclosed and approved by the express written consent of the Lender, for a period of twelve (12) months from the date hereof, the Company
shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of
shares of Class A Common Stock or Common Stock Equivalents (as defined in the Note) (or a combination of units thereof) involving a Variable
Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt
or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of
Class A Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies
with the trading prices of or quotations for the shares of Class A Common Stock at any time after the initial issuance of such debt or
equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the
initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Class A Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price, or an
at-the-market offering. Any Lender shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which
remedy shall be in addition to any right to collect damages.
h.
No Defaults. No event has occurred and no condition exists which would constitute an Event of Default pursuant to this Loan Agreement.
Company is not in violation in any material respect of any term of any agreement, charter instrument, bylaw or other instrument to which
it is a party or by which it may be bound, where the violation would have a Material Adverse Effect.
i.
Taxes. All tax returns required to be filed by the Company in any jurisdiction have in fact been filed, and all taxes, assessments,
fees and other governmental charges upon the Company, or upon any of its properties, which are due and payable have been paid. Company
does not know of any proposed additional tax assessment against it. The accruals for taxes on the books of the Company for its current
fiscal period are adequate.
j.
Compliance with Law. Company (a) is not in violation of any state laws, ordinances, governmental rules or regulations to which
it is subject and (b) has not failed to obtain any licenses, permits, franchises or other governmental or environmental authorizations
necessary to the ownership of its properties or to the conduct of its business, which violation or failure might materially and adversely
affect the business, prospects, profits, properties or condition (financial or otherwise) of the Company.
k.
Consents and Approvals. Except as set forth in this Section 9(k), neither the nature of the Company or of its business or properties,
nor any relationship between the Company and any other entity or person, nor any circumstance in connection with the execution of this
Loan Agreement, is such as to require a consent, approval or authorization of, or filing, registration or qualification with, any governmental
authority on the part of the Company as a condition to the execution and delivery of this Loan Agreement and the notes and documents
contemplated herein (collectively, the “Required Approvals”). For the avoidance of doubt, compliance with Nasdaq Listing
Rule 5635(d) shall be a Required Approval. Specifically, the Company shall not effect the conversion of any of the Class A Common Stock
under the Note, or the exercise of any Warrant held by an Lender, or pay any dividend in the form of common stock, and an Lender shall
not have the right to convert any of the Class A Common Stock or exercise Warrants held by such Lender and any such conversion or exercise
shall be null and void and treated as if never made, if to the extent that after giving effect to such payment of dividend in the form
of common stock, or such conversion of the Note or exercise of such Warrant, the aggregate outstanding shares of all classes of the Company’s
common stock issuable to the Lender would exceed, when added to the previously issued shares of Class A Common Stock under the Transaction
Documents, the requirements of Nasdaq Listing Rule 5635(d) (“Nasdaq 19.99% Cap”), except that such limitation will not apply
at any time following Shareholder Approval. The date in which the Nasdaq 19.99% Cap is calculated shall be the date immediately preceding
the issuance of the securities before the issuance of the Warrant and Note.
l.
Material Adverse Effect. There are no pending or threatened claims against the Company in excess of $50,000 or alleging a class
action against the Company. There is no action, suit, audit, proceeding, investigation or arbitration (or series of related actions,
suits, proceedings, investigations or arbitrations) pending before or by any governmental authority or private arbitrator or, to the
knowledge of the Company, threatened against the Company or any property of the Company (a) challenging the validity or the enforceability
of any of this Loan Agreement, or any loan document, agreement, or instrument executed in connection herewith, or (b) which has had,
shall have or is reasonably likely to have a Material Adverse Effect. Company is not in violation of any applicable requirements of state
law which violation shall have or is likely to result in a Material Adverse Effect, or subject to or in default with respect to any final
judgment, writ, injunction, restraining order or order of any nature, decree, rule or regulation of any court or governmental authority,
in each case which shall have or is likely to have a Material Adverse Effect. Further, no other circumstances or conditions exist that
shall have or is reasonably likely to have a Material Adverse Effect on the Company. As used in this Loan Agreement, “Material
Adverse Effect” means a material adverse effect upon (aa) the business, condition (financial or otherwise), operations, performance,
properties or prospects of the Company or any guarantor, (bb) the ability of the Company or any guarantor to perform its obligations
under this Loan Agreement or any document, agreement, guaranty, or instrument executed in connection herewith, or (cc) the ability of
Lender to enforce the terms of this Loan Agreement, or any document, agreement, guaranty, or instrument executed in connection herewith.
m.
Nasdaq 20% Rule. The transaction or series of transactions under the Transaction Documents may constitute the issuance or potential
issuance by the Company of securities convertible into or exercisable for common stock equal to 20% or more of the aggregate outstanding
shares of all classes of the Company’s common stock or 20% or more of the voting power outstanding before the issuance of for less
than the Minimum Price. “Minimum Price” means a price that is the lower of: (i) the Nasdaq official closing price (as reflected
on Nasdaq.com) immediately preceding the signing of the binding agreement; or (ii) the average Nasdaq official closing price of the common
stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the binding agreement. Further, Nasdaq
shall likely conclude the Transaction Documents between the parties and a substantially similar set of transaction documents between
the Company and a third party, with a date contemporaneous hereof, shall be part of a single plan of financing and shall therefore be
aggregated for the purposes of the Nasdaq 19.99% Cap. Consequently, the Company shall seek Shareholder Approval, in accordance with Section
8 of this Agreement, prior to the issuance of securities in excess of the Nasdaq 19.99% Cap in connection with the transaction in accordance
with Nasdaq Rule 5635(d).
n.
Foreign Corrupt Practices Act. Except as otherwise disclosed in the Company’s SEC reports, neither the Company nor, to the
Company’s knowledge, any of its affiliates, directors, officers, employees, agents or other person acting on behalf of the Company
is aware of or has taken any action, directly or indirectly, that would result in a material violation by such person of the Foreign
Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation,
making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise
to pay or authorization of the payment of money, or other property, gift, promise to give, or authorization of the giving of anything
of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof
or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the Company’s knowledge, its
affiliates have conducted their businesses in material compliance with the FCPA and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.
o.
Rule 506(d) Bad Actor Disqualification Representations and Covenants.
(i)
No Disqualification Events. Neither the Company, nor any of its predecessors, affiliates, any manager, executive officer, other
officer of the Company participating in the offering, any beneficial owner (as that term is defined in Rule 13d-3 under the Exchange
Act) of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity as of the date of this Agreement
and on the Closing Dates (each, a “Company Covered Person” and, together, “Company Covered Persons”) is subject
to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to
determine (A) the identity of each person that is a Company Covered Person; and (B) whether any Company Covered Person is subject to
a Disqualification Event. The Company will comply with its disclosure obligations under Rule 506(e).
(ii)
Other Covered Persons. The Company is not aware of any person (other than any Company Covered Person) who has been or will be
paid (directly or indirectly) remuneration in connection with the purchase and sale of the Notes, the Warrants and/or the Commitment
Shares who is subject to a Disqualification Event (each, an “Other Covered Person”).
(iii)
Reasonable Notification Procedures. With respect to each Company Covered Person, the Company has established procedures reasonably
designed to ensure that the Company receives notice from each such Company Covered Person of (A) any Disqualification Event relating
to that Company Covered Person, and (B) any event that would, with the passage of time, become a Disqualification Event relating to that
Company Covered Person; in each case occurring up to and including the Closing Dates.
(iv)
Notice of Disqualification Events. The Company will notify the Lender immediately in writing upon becoming aware of (A) any Disqualification
Event relating to any Company Covered Person and (B) any event that would, with the passage of time, become a Disqualification Event
relating to any Company Covered Person and/or Other Covered Person.
p.
Sarbanes-Oxley; Internal Accounting Controls. Except as set forth in the SEC Reports, the
Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective
as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as
of the date hereof and as of the Closing Dates. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset
accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and
(iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures
to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s
certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as
of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation
Date”). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its subsidiaries.
q.
Insurance. Except as set forth in the SEC Reports, the Company is insured by insurers of
recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the business in
which it is engaged; the Company has not been refused any coverage sought or applied for; and the Company does not have any reason to
believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect on the Company.
r.
Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’
employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.
s.
Dilutive Effect. The Company understands and
acknowledges that the number of Conversion Shares issuable upon conversion of the Notes, pursuant to the terms thereof, will increase
in certain circumstances. The Company further acknowledges that its obligations to issue Conversion Shares pursuant to the terms of the
Notes in accordance with this Agreement and the Notes and to issue Warrant Shares upon exercise of the Warrants in accordance with this
Agreement and the Warrants are, in each case, absolute and unconditional regardless of the dilutive effect that any such issuances may
have on the percentage ownership interests of other stockholders of the Company.
t.
Application of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary action,
if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provisions under the Company’s certificate of incorporation, as amended,
or the laws of the jurisdiction of its formation that are or could become applicable to the Lender as a result of the transactions contemplated
by this Agreement and/or the other Transaction Documents, including, without limitation, the Company’s issuance of the Securities
and the Lender’s ownership of the Securities. The Company has not adopted a stockholder rights plan or similar arrangement relating
to accumulations of beneficial ownership of Class A Common Stock or a change in control of the Company.
u.
DTC Eligible. The Class A Common Stock is DTC eligible and DTC has not placed a “freeze” or a “chill”
on the Class A Common Stock and the Company has no reason to believe that DTC has any intention to make the Class A Common Stock not
DTC eligible, or place a “freeze” or “chill” on the Class A Common Stock.
v.
Listing and Maintenance Requirements. The Class A Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Class A Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof,
received notice from any Trading Market on which the Class A Common Stock are or have been listed or quoted to the effect that the Company
is not in compliance with the listing or maintenance requirements of such Trading Market. The Class A Common Stock is eligible for quotation
on the Principal Market and the Company has no reason to believe that the Principal Market has any intention of delisting the Class A
Common Stock from the Principal Market. The issuance and sale of the Securities hereunder does not contravene the rules and regulations
of the Trading Market. All Underlying Shares have been approved, if so required, for listing or quotation on the Trading Market, subject
only to notice of issuance.
w.
No General Solicitation. Neither the Company, nor any of its affiliates, nor, to the knowledge of the Company, any Person acting
on its behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection
with the offer or sale of the underlying securities.
x.
Off-Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated
or other off-balance sheet entity that is required to be disclosed by the Company in its Exchange Act filings and is not so disclosed
or that otherwise would be reasonably likely to have a Material Adverse Effect.
y.
Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted
at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively,
the “Money Laundering Laws”), and no Action or Proceeding by or before
any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money
Laundering Laws is pending or, to the knowledge of the Company or any subsidiary, threatened.
z.
Environmental Laws. The Company and its Subsidiaries, to the best of the Company’s
knowledge, (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health
or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to
emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes
(collectively, “Hazardous Materials”) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.
10.
REPRESENTATIONS AND WARRANTIES BY LENDER. Lender, by the acceptance of this Note, represents and warrants to Company as follows:
a.
Lender is acquiring the Notes with the intent to hold as an investment and not with a view of distribution.
b.
Lender is an “accredited investor” within the definition contained in Rule 501(a) under the Securities Act of 1933, as amended
(the “Securities Act”), and is acquiring the Notes for its own account, for investment, and not with a view to, or for sale
in connection with, the distribution thereof or of any interest therein. Lender has adequate net worth and means of providing for its
current needs and contingencies and is able to sustain a complete loss of the investment in the Notes, and has no need for liquidity
in such investment. Lender, itself or through its officers, employees or agents, has sufficient knowledge and experience in financial
and business matters to be capable of evaluating the merits and risks of an investment such as an investment in the Securities, and Lender,
either alone or through its officers, employees or agents, has evaluated the merits and risks of the investment in the Notes.
c.
Lender acknowledges and agrees that it is purchasing the Notes hereunder based upon its own inspection, examination and determination
with respect thereto as to all matters, and without reliance upon any express or implied representations or warranties of any nature,
whether in writing, orally or otherwise, made by or on behalf of or imputed to the Company.
11.
LIQUIDATED DAMAGES.
a.
In the event of a Registration Default, the Company hereby agrees to pay to the Lender Liquidated Damage Penalty as set forth in Section
7 until the Registration Statement takes effective. Following the cure of all Registration Defaults relating to any particular registrable
Securities, Liquidated Damages shall cease to accrue; provided, however, that, if after Liquidated Damages have ceased to accrue, a different
Registration Default occurs, Liquidated Damages shall again accrue pursuant to the foregoing provisions. Any amounts due under this Section
shall be paid by the fifth (5th) day of the month following the month in which they accrued.
b.
The Company and Lender hereto acknowledge and agree
that the sums payable as Liquidated Damages under subsection 11(a) and Section 12 shall constitute liquidated damages and not
penalties and are in addition to all other rights of the Lender, including the right to call a default under the Loan Agreement. The
parties further acknowledge that (i) the amount of loss or damages likely to be incurred is incapable or is difficult to precisely estimate,
(ii) the amounts specified in such subsections bear a reasonable relationship to, and are not plainly or grossly disproportionate to,
the probable loss likely to be incurred in connection with any failure by the Company to obtain or maintain the effectiveness of a registration
statement, (iii) one of the reasons for the Company and the Lender reaching an agreement as to such amounts was the uncertainty and cost
of litigation regarding the question of actual damages, and (iv) the Company and the Lender are sophisticated business parties and have
been represented by sophisticated and able legal counsel and negotiated this Agreement at arm’s length.
12.
ORDINARY SHARE ISSUANCE. Upon receipt by the Company of a written request from Lender to convert any amount due under any
Note or to exercise any portion of any Warrant, subject to any limitations on conversion or exercise contained in any Note and/or Warrant,
the Company shall have three (3) business days (“Delivery Date”) to issue the Class A Common Stock rightfully listed in such
request. If the Company fails to timely deliver the shares, the Company shall pay to Lender in immediately available funds $1,000.00
per business day past the Delivery Date that the shares are actually issued. Any amounts due under this Section shall be paid by the
fifth (5th) day of the month following the month in which they accrued or, at the option of Lender, may be added to the principal
under any Note. The Company agrees that the right to convert the Note or exercise its Warrants is a valuable right to Lender and a material
consideration of it entering this Agreement. The parties agree that it would be impracticable and extremely difficult to ascertain the
amount of actual damages caused by a failure of the Company to timely deliver shares as required hereby. Therefore, the parties agree
that the foregoing liquidated damages provision represents reasonable compensation for the loss which would be incurred by the Lender
due to any such breach. The parties agree that this Section is not intended to in any way limit Lender’s right to pursue other
remedies, including actual damages and/or equitable relief.
13.
EVENTS OF DEFAULT. An event of default will occur if any of the following circumstances occur (each an “Event of Default”):
a.
Any representation or warranty made by Company in this Agreement or in connection with any Warrant or Note, or in any financial statement,
or any other statement furnished by Company to Lender is untrue in any material respect at the time when made or becomes untrue;
b.
Default by Company in the observance or performance of any other covenant or agreement contained
in this Agreement;
c.
Default by Company under the terms of any Note, Warrant, Registration Agreement or any other
third party note or warrant that exceeds a value of $500,000;
d.
Filing by Company of a voluntary petition in bankruptcy seeking reorganization, arrangement
or readjustment of debts, or any other relief under the Bankruptcy Code as amended or under any other insolvency act or law, state or
federal, now or hereafter existing;
e.
Filing of an involuntary petition against Company in bankruptcy seeking reorganization, arrangement or readjustment
of debts, or any other relief under the Bankruptcy Code as amended, or under any other insolvency act or law, state or federal,
now or hereafter existing, and the continuance thereof for sixty (60) days undismissed, unbonded or undischarged;
f.
Company liquidates, transfers, sells or assigns substantially its assets or elects to wind down its operations or dissolve;
g.
The Company fails to maintain the TA Instruction Letter, file with the Company’s transfer agent, or update the TA Instruction Letter
to increase the reserve shares as needed, along with a reserve of Class A Common Stock sufficient to satisfy the Notes and Warrants based
on a then hypothetical conversion scenario per the terms of the Note and the Warrant Shares;
h.
The Company fails to maintain DTC or DWAC eligibility;
i.
The Company fails to stay current in its SEC reporting obligations or maintain its continued listing of the Company’s Class A Common
Stock on Nasdaq Global Market or Nasdaq Capital Market;
j.
The Company fails to deliver Lender the Class A Common Stock rightfully listed in any Conversion Notice or any Warrants Exercise Notice
within three (3) business days of receipt of such notice(s);
k.
The Company breaches any other agreement it has with Lender or his assigns;
l.
The Company interferes with Lender’s or its assigns’ efforts to remove the restrictive legend from the Class A Common Stock
issued as a result of conversion of any Note when Lender or his assign has provided a reasonable attorney opinion letter from a reputable
law firm opining that the shares are eligible to have the legend removed pursuant to Rule 144 or otherwise;
m.
The occurrence of a Registration Default; and
n.
The Company issues, grants or sells an additional issuance on contrast to Section 9(g) of this Agreement.
14.
REMEDIES. (i) There will be no cure period available for the Event of Default as defined in Section 13(d), 13(e) and 13(m);
or (ii) upon the occurrence of any other Event of Default as defined above, and provided such Event of Default has not been cured by
the Company within ten (10) business days after written notice of the occurrence of such Event of Default, the principal and any accrued
interest of the Note will be due immediately, and Lender shall have all of the rights and remedies provided by applicable law and equity.
In the event of a default under Section 13(m), the sole penalty shall be as provided for in Section 11 hereof and as provided in the
Note. To the extent permitted by law, Company waives any rights to presentment, demand, protest, or notice of any kind in connection
with this Agreement, any Warrant and/or any Note. No failure or delay on the part either party in exercising any right, power, or privilege
hereunder or thereunder will preclude any other or further exercise thereof or the exercise of any other right, power, or privilege.
The rights and remedies provided herein are cumulative and not exclusive of any other rights or remedies provided at law or in equity.
Following the closing of the Business Combination, in the event Lender shall refer this Agreement to an attorney to enforce the terms
hereof, the Company agrees to pay all the costs and expenses incurred in attempting or effecting the enforcement of the Lender’s
rights, including reasonable attorney’s fees, whether or not suit is instituted.
15.
PUBLIC INFORMATION. After the closing of
the Business Combination, except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide the Lender or its
agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information,
unless prior thereto the Lender shall have consented to the receipt of such information and agreed with the Company to keep such information
confidential. The Company understands and confirms that the Lender shall be relying on the foregoing covenant in effecting transactions
in securities of the Company. To the extent that the Company delivers any material, non-public information
to a Lender without such Lender’s consent, the Company hereby covenants and agrees that such Lender shall not have any duty of
confidentiality to the Company, any of its subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates,
or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not
to trade on the basis of, such material, non-public information, provided that the Lender
shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The
Company understands and confirms that the Lender shall be relying on the foregoing covenant in effecting transactions in securities of
the Company.
16.
INDEMNIFICATION OF LENDER. Subject to the
provisions of this Section 16, the Company will indemnify and hold the Lender and its directors, officers, shareholders, members, partners,
employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title), each Person who controls such Lender (within the meaning of Section 15 of the Securities Act and Section
20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with
a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling
persons (each, a “Lender Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, as incurred, arising out of or relating to (i) any untrue or alleged
untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment
or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto,
in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that such
untrue statements or omissions are based solely upon information regarding such Lender Party furnished in writing to the Company by such
Lender Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the Exchange
Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall be brought against
any Lender Party in respect of which indemnity may be sought pursuant to this Agreement, such Lender Party shall promptly notify the
Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Lender Party. Any Lender Party shall have the right to employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Lender Party except to the extent that (x) the employment
thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable period of time to assume
such defense and to employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material conflict on any material
issue between the position of the Company and the position of such Lender Party, in which case the Company shall be responsible for the
reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Lender Party under this
Agreement (1) for any settlement by a Lender Party effected without the Company’s prior written consent, which shall not be unreasonably
withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Lender
Party’s breach of any of the representations, warranties, covenants or agreements made by such Lender Party in this Agreement or
in the other Transaction Documents. The indemnification required by this Section 16 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Lender Party against the Company or others and any liabilities
the Company may be subject to pursuant to
17.
FORM D; BLUE SKY FILINGS. The Company agrees
to timely file a Form D with respect to the securities as required under Regulation D and to provide a copy thereof, promptly upon request
of any Lender. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption
for, or to qualify the Securities for, sale to the Lender at the applicable Closing under applicable securities or “Blue Sky”
laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Lender.
18.
NOTICE. Any and all notices, demands, advance requests or other communications required or desired to be given hereunder by any
party shall be in writing and shall be validly given or made to another party if (i) personally served, (ii) sent by email on the date
such email is sent (provided confirmation of such email being sent is provided upon request) (iii) deposited in the United States mail,
postage prepaid, return receipt requested, or (iv) by facsimile with confirmation receipt. Notice hereunder is to be given as follows:
If
to the Company:
Deep
Medicine Acquisition Corp.
1096
Keeler Avenue
Berkeley,
CA 94708
Email:
Humphrey.polanen@gmail.com
Attn:
Humphrey P. Polanen
If
to the Lender:
Greentree
Financial Group, Inc.
1000
S. Pine Island Road, Suite 210
Plantation,
FL 33324
Email:
chriscottone@gtfinancial.com
Attn:
R. Chris Cottone
With
a copy to (which does not constitute Notice):
Austin
Legal Group
3990
Old Town Ave. Suite A-101
San
Diego, CA 92110
Email:
gaustin@austinlegalgroup.com
Attn:
Gina Austin
19.
USURY. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at
any time hereafter in force, in connection with any action or proceeding that may be brought by any Lender in order to enforce any right
or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any Transaction Document, it is
expressly agreed and provided that the total liability of the Company under the Transaction Documents for payments in the nature of interest
shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum
Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default
interest, or both of them, when aggregated with any other sums in the nature of interest that the Company may be obligated to pay under
the Transaction Documents exceed such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable
to the Transaction Documents is increased or decreased by statute or any official governmental action subsequent to the date hereof,
the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from the effective
date thereof forward, unless such application is precluded by applicable law. If under any circumstances whatsoever, interest in excess
of the Maximum Rate is paid by the Company to any Lender with respect to indebtedness evidenced by the Transaction Documents, such excess
shall be applied by such Lender to the unpaid principal balance of any such indebtedness or be refunded to the Company, the manner of
handling such excess to be at such Lender’s election.
20.
GENERAL PROVISIONS. All representations and warranties made in the Transaction Documents shall survive the execution and delivery
of this Agreement and the making of any Loans hereunder. This Agreement will be binding upon and inure to the benefit of Company and
Lender, their respective successors and assigns.
21.
ENTIRE AGREEMENT. The Transaction Documents contain the entire agreement of the parties and supersedes and replaces all prior
discussions, negotiations and representations of the parties. No party shall rely upon any oral representations in entering into this
agreement, such oral representations, if any, being expressly denied by the party to whom they are attributed and it being the intention
of the parties to limit the terms of this Agreement to those matters contained herein in writing. However, the incorporated Note shall
be deemed controlling at all times with regards to any inconsistent or changed terms or amendments contained therein.
22.
BINDING EFFECT. This agreement is binding upon and inures to the benefit of the parties hereto, their heirs, personal representatives,
successors and assigns. Lender may assign their rights hereunder without prior permission from the Company. The Company may not assign
their rights or obligations hereunder without the express written consent of the Lender, which may be withheld at its discretion.
23.
GOVERNING LAW AND CONSENT TO JURISDICTION. Except as other otherwise provided herein, this Agreement shall be governed by
and construed in accordance with the laws of the State of Nevada without regard to conflict of law provisions. Each of the parties to
this Agreement irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the courts of the
State of Florida and of the United States District Court of the Southern District of Florida, and any appellate court from any thereof,
in any action or proceeding arising out of or relating to this Agreement, or for the recognition or enforcement of any judgment, and
each of the parties hereto irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be
heard and determined in such Florida State court or, to the fullest extent permitted by applicable law, in such federal court. Each of
the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by law. The Company further waives any objection to venue in any such action
or proceeding on the basis of inconvenient forum. The Company agrees that any action on or proceeding brought against the Lender shall
only be brought in such courts. Notwithstanding anything to the contrary above, Section 30 of this Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware without regard to conflict of law provisions.
24.
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.
25.
ATTORNEYS FEES. Following the Business Combination, in the event the Lender hereof shall refer this Agreement to an attorney
to enforce the terms hereof, the Company agrees to pay all the costs and expenses incurred in attempting or effecting the enforcement
of the Lender’s rights, including reasonable attorney’s fees, whether or not suit is instituted.
26.
AMENDMENT. The terms of this Agreement may not be amended, modified, or eliminated without written consent of the parties.
27.
SEVERABILITY. Every provision of this Agreement is intended to be severable. If any term or provision thereof is illegal or
invalid for any reason whatsoever, such illegality or invalidity shall not affect the validity or legality of the remainder of this Agreement.
28.
CONSTRUCTION. Section and paragraph headings are for convenience only and do not affect the meaning or interpretation of this
Agreement. No rule of construction or interpretation that disfavors the party drafting this Agreement or any of its provisions will apply
to the interpretation of this Agreement. Instead, this Agreement will be interpreted according to the fair meaning of its terms.
29.
FURTHER ASSURANCES. Each party hereto agrees to do all things, including execute, acknowledge and/or deliver any documents
which may be reasonably necessary, appropriate or desirable to effectuate the transactions contemplated herein pursuant to terms and
conditions of this Agreement.
30.
WAIVER AGAINST TRUST. Reference is made to the final prospectus of SPAC, dated as of October 26, 2021 and filed with the SEC
(File No. 333-260515) on October 28, 2021 (the “Prospectus”). Lender hereby represents and warrants that it has read the
Prospectus and understands that SPAC has established a trust account (the “Trust Account”) containing the proceeds of its
initial public offering (the “IPO”) and the overallotment securities acquired by its underwriters and from certain private
placements occurring simultaneously with the IPO (including interest accrued from time to time thereon) for the benefit of SPAC’s
public stockholders (including overallotment shares acquired by SPAC’s underwriters, the “Public Stockholders”), and
that, except as otherwise described in the Prospectus, SPAC may disburse monies from the Trust Account only: (a) to the Public Stockholders
in the event they elect to redeem their SPAC shares in connection with the consummation of SPAC’s initial business combination
(as such term is used in the Prospectus) (the “Business Combination”) or in connection with an extension of its deadline
to consummate a Business Combination, (b) to the Public Stockholders if SPAC fails to consummate a Business Combination within twelve
(12) months after the closing of the IPO, subject to extension in accordance with SPAC’s organizational documents, (c) with respect
to any interest earned on the amounts held in the Trust Account, amounts necessary to pay for any taxes and up to $50,000 in dissolution
expenses or (d) to SPAC after or concurrently with the consummation of a Business Combination. For and in consideration of SPAC entering
into this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Lender
hereby agrees on behalf of itself and its affiliates that, notwithstanding anything to the contrary in this Agreement, neither Lender
nor any of its affiliates do now or shall at any time hereafter have any right, title, interest or claim of any kind in or to any monies
in the Trust Account or distributions therefrom, or make any claim against the Trust Account (including any distributions therefrom),
regardless of whether such claim arises as a result of, in connection with or relating in any way to, this Agreement or any proposed
or actual business relationship between SPAC or its Representatives, on the one hand, and Lender or its Representatives, on the other
hand, or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other theory of legal liability
(collectively, the “Released Claims”). Lender on behalf of itself and its affiliates hereby irrevocably waives any Released
Claims that Lender or any of its affiliates may have against the Trust Account (including any distributions therefrom) now or in the
future as a result of, or arising out of, any negotiations, contracts or agreements with SPAC or its Representatives and will not seek
recourse against the Trust Account (including any distributions therefrom) for any reason whatsoever (including for an alleged breach
of this Agreement or any other agreement with SPAC or its affiliates). Lender agrees and acknowledges that such irrevocable waiver is
material to this Agreement and specifically relied upon by SPAC and its affiliates to induce SPAC to enter in this Agreement, and Lender
further intends and understands such waiver to be valid, binding and enforceable against Lender and each of its affiliates under applicable
law. To the extent Lender or any of its affiliates commences any action or proceeding based upon, in connection with, relating to or
arising out of any matter relating to SPAC or its Representatives, which proceeding seeks, in whole or in part, monetary relief against
SPAC or its Representatives, Lender hereby acknowledges and agrees that Lender’s and its affiliates’ sole remedy shall be
against funds held outside of the Trust Account and that such claim shall not permit Lender or its affiliates (or any person claiming
on any of their behalves or in lieu of any of them) to have any claim against the Trust Account (including any distributions therefrom)
or any amounts contained therein. In the event Lender or any of its affiliates commences any action or proceeding based upon, in connection
with, relating to or arising out of any matter relating to SPAC or its Representatives, which proceeding seeks, in whole or in part,
relief against the Trust Account (including any distributions therefrom) or the Public Stockholders, whether in the form of money damages
or injunctive relief, SPAC and its Representatives, as applicable, shall be entitled to recover from Lender and its affiliates the associated
legal fees and costs in connection with any such action, in the event SPAC or its Representatives, as applicable, prevails in such action
or proceeding. For the avoidance of doubt, the provisions of this paragraph 8 shall not restrict the Lender in its capacity as a Public
Stockholder, if applicable, from redeeming any shares of SPAC that it owns in accordance with SPAC’s organizational documents and
the Prospectus.
IN
WITNESS WHEREOF, the parties hereto enter into this Loan Agreement which is effective as of the date first written.
Company: |
|
Lender: |
|
|
|
|
|
Deep
Medicine Acquisition Corp. |
|
Greentree
Financial Group, Inc. |
|
|
|
|
|
By: |
/s/
Humphrey P. Polanen |
|
By: |
/s/
R. Chris Cottone |
Name: |
Humphrey
P. Polanen |
|
Name: |
R.
Chris Cottone |
Title: |
Chief
Executive Officer |
|
Title: |
Vice
President |
EXHIBIT
A
CONVERTIBLE
NOTE
[See
Attached]
EXHIBIT
B
WARRANT
AGREEMENT
[See
Attached]
EXHIBIT
C
REGISTRATION
RIGHTS AGREEMENT
[See
Attached]
EXHIBIT
D
TA
INSTRUCTION LETTER
[See
Attached]
Exhibit
10.2
Loan
Agreement
LOAN
AGREEMENT
This
Loan Agreement (“Agreement”) is made and entered into in this 2nd day of November 2023 (“Effective Date”),
by and between Deep Medicine Acquisition Corp., a Delaware corporation, its successors and assigns (the “Company” and before
the closing of the Business Combination, the “SPAC”), and Finuvia, LLC, a Delaware limited liability company (the “Lender”).
RECITALS
WHEREAS,
the Company entered into an Amended and Restated Agreement and Plan of Merger (as may be amended from time to time, the “Merger
Agreement”) with DMAC Merger Sub Inc., a Nevada corporation and newly formed wholly-owned subsidiary of the Company (“Merger
Sub”), Bright Vision Sponsor LLC, a Delaware limited liability company, solely in the capacity as the representative from and after
the effective time of the Merger (as defined in the Restated Merger Agreement) (the “Effective Time”) for the stockholders
of the Company (other than the TruGolf stockholders) (the “Purchaser Representative”), TruGolf, Inc., a Nevada corporation
(“TruGolf”) and Christopher Jones, an individual, solely in his capacity as the representative from and after the Effective
Time for the TruGolf stockholders (the “Seller Representative”);
WHEREAS,
subject to the terms and conditions set forth in the Merger Agreement, upon the consummation of the transactions contemplated thereby,
Merger Sub will merge with and into TruGolf, with TruGolf surviving as a wholly-owned subsidiary of the Company (the “Business
Combination”), and with TruGolf’s equity holders receiving shares of the Company’s common stock;
WHEREAS,
the Company desires working capital and the Lender has agreed to provide up to Two Million Five Hundred Thousand Dollars ($2,500,000.00)
of such capital following the closing of the Business Combination and according to the terms hereof;
WHEREAS,
the Lender and Company are entering into this Agreement to establish terms by which the Lender shall fund the Loans, as set forth herein
and therein the related Note, described below, and the Company shall issue warrants as set forth herein and therein the related Warrant,
described below; and
WHEREAS,
simultaneously the Lender and the Company are entering into that certain Registration Rights Agreement, described below.
AGREEMENT
NOW,
THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the sufficiency
of which is acknowledged by the Lender and Company (each “party” and, collectively, “parties”), the parties hereby
agree as follows:
1.
LOANS; PROMISSORY NOTE. The Lender shall loan the Company up to Two Million Five Hundred Thousand Dollars $2,500,000 (the
“Principal Amount”) with a 10% original issuance discount, pursuant to the terms hereof; provided, nothing herein or otherwise
shall obligate Lender to make any future loans to the Company. All sums advanced pursuant to the terms of this Agreement (a “Loan”)
shall be evidenced by a separate convertible promissory note (each a “Note”), in substantially the form set forth as Exhibit
A hereto. The Note shall be convertible into shares of the Company’s Class A common stock (the “Class A Common Stock”)
pursuant to the terms contained in the Note. All covenants, conditions and agreements contained herein are made a part of the Note, unless
modified therein.
a.
Unless stated otherwise in the Note, the Note will automatically mature five (5) years from the effective date of each applicable Note
(such date, the “Maturity Date”).
b.
All sums advanced pursuant to this Agreement shall bear interest as set forth in Section 2 of the Note.
2.
WARRANTS. On the First Closing Date (as defined below), the Company shall simultaneously issue to the Lender, a warrant in
substantially the form annexed hereto as Exhibit B (the “Warrant”) to purchase an aggregate of Two Hundred Twenty-Seven Thousand
Two Hundred Seventy-Three (227,273) shares of Class A Common Stock (the “Warrant Shares”) at an initial exercise price of
Thirteen Dollars ($13.00) per share (the “Exercise Price”).
3.
PREPAYMENT. The Company may, at its option, at any time and from time to time, prepay all or any part of the principal balance
of the Note before the Maturity Date as set forth in the Note, without any penalty, subject to notice requirements in the Note. In the
event of prepayment, the Lender shall retain the Warrants. Notwithstanding the foregoing, the Company shall provide ten (10) day written
notice, in accordance with Section 18, if it intends to prepay all or any part of the principal balance of this Note before the Maturity
Date during the first six (6) months following the Closing Date of each respective Note.
4.
CLOSING. Each respective closing date shall be on such date in which this Agreement is duly executed
and the closing conditions of this Section 4 have been satisfied or otherwise waived by the Lender or Company, respectfully (each, a
“Closing Date” and collectively, the “Closing Dates”).
1) |
The
obligation of Lender to fund the First Tranche (as defined below) hereunder shall be subject to the following conditions precedent,
each in form and substance reasonably satisfactory to, and to the satisfaction of, the Lender (the “First Closing Date”): |
|
a) |
the
representations and warranties contained in the Transaction Documents (as defined below) are true and correct in all material respects
as of the issue date of the Note(s), both before and after giving effect to the transactions contemplated by the Transaction Documents; |
|
b) |
no
Event of Default shall have occurred and is continuing or would occur as a result of the Transaction Documents; |
|
c) |
receipt
by the Lender of the duly executed Agreement; |
|
d) |
receipt
by the Lender of the executed copies of the Note; |
|
e) |
receipt
by the Lender of executed copies of the Warrants; |
|
f) |
receipt
of the Lender of the duly executed Registration Rights Agreement; |
|
g) |
the
closing of the Business Combination; |
|
h) |
the
Company being listed on the Nasdaq Capital Market or the Nasdaq Global Market after the closing of the Business Combination; and |
|
i) |
the
Company’s transfer agent’s confirmation of receipt of the TA Instruction Letter. |
2) |
The
obligation of Lender to fund the Second Tranche (as defined below) hereunder shall be subject to the following conditions precedent,
each in form and substance reasonably satisfactory to, and to the satisfaction of, the Lender (the “Second Closing Date”): |
|
a) |
the
satisfaction of the conditions precedent in Section 4(1); |
|
b) |
Shareholder
Approval of the Transaction Documents; and |
|
c) |
the
Company exercising its discretion in accordance with Section 6 of this Agreement. |
3) |
The
obligation of Lender to fund the Third Tranche hereunder shall be subject to the following conditions precedent, each in form and
substance reasonably satisfactory to, and to the satisfaction of, the Lender (the “Final Closing Date”): |
|
a) |
the
satisfaction of the conditions precedent in Section 4(1); |
|
b) |
Shareholder
Approval of the Transaction Documents; and |
|
c) |
the
Company exercising its discretion in accordance with Section 6 of this Agreement. |
5.
ALLOWANCE FOR LEGAL FEE. There will be a $25,000 allowance for Lender’s legal fees paid by the Company and deducted
from Lender’s payment, payable as set forth in Section 6 below.
6.
PAYMENT TERMS. Upon satisfaction of the conditions set forth in Section 4 hereof, the signing
of this Agreement and the receipt of a Note in principal amount of $750,000, the Lender will pay the Company $650,000, net of original
issuance discount and the allowance for legal fees specified in Section 5 hereof (the “First Tranche”). At the Company’s
discretion, within three (3) business days after the filing of the Registration Statement (as defined below), upon satisfaction of the
conditions set forth in Section 4 hereof and the receipt of a Note in principal amount of $750,000, the Lender will pay the Company $675,000,
net of original issuance discount (the “Second Tranche”). At the Company’s discretion, within three (3) business days
after the Registration Statement is effective, upon satisfaction of the conditions set forth in Section 4 hereof and the receipt of a
Note in principal amount of $1,000,000, the Lender will pay the Company $900,000, net of original issuance discount (the “Third
Tranche”). Until such time that the Company files the Registration Statement and it is declared effective, Lender shall have no
obligation to fund the Second Tranche or the Third Tranche, respectively. Should the Company exercise its discretion and opt to forgo
receiving Second Tranche or Third Tranche, it shall provide the Lender written notice in accordance with Section 18 no less than three
(3) business days prior to the filing and effectiveness of the Registration Statement. Further, if the Company fails to meet its obligations
to file Registration Statement and have it declared effective in accordance with Section 7 of this Agreement and the Registration Rights
Agreement, and the terms and conditions of the Note and Warrant, it shall be subject to the Liquidated Damages Penalty.
7.
REGISTRATION RIGHTS. Simultaneously to the Agreement, the Company and the Lender shall execute a registration rights agreement
in substantially the form annexed hereto as Exhibit C (the “Registration Rights Agreement”). In accordance with the
terms and conditions of the Registration Rights Agreement, the Company shall prepare and file with the United States Securities and Exchange
Commission (the “Commission” or “SEC”) a registration statement on Form S-1 or Form S-3 (the “Form S-1”,
“Form S-3”, or “Registration Statement”), to the extent permitted under the applicable law and by the Commission,
within 30 days from the closing of the Business Combination (the “Filing Date”) to the Class A Common Stock underlying all
of the Notes and Warrants issuable hereunder, assuming the full conversion of the Notes into shares of Class A Common Stock and the payment
of all interest on the Notes in shares of Class A Common Stock at the “floor” price set forth in the Notes and the Warrant.
The Registration Statement must be effective within 75 days from the Filing Date (the “Effectiveness Date”). There shall
be monthly liquidated damages equal to 2.0% of the Principal Amount (the “Liquidated Damage Penalty”) if (i) the Registration
Statement is not filed on or prior to its Filing Date, (ii) a Registration Statement is not declared effective by the Commission or does
not otherwise become effective on or prior to its required Effectiveness Date and/or (iii) after its effective date, such Registration
Statement ceases for any reason to be effective as to all Registrable Securities (as defined in the Registration Rights Agreement) to
which it is required to cover at any time prior to the expiration of the Effectiveness Period (any such failure or breach being referred
to as a “Registration Default”), which damages shall accrue each month until the applicable breach (failure to timely file,
failure to timely have declared effective, or ceasing to be effective) has been cured. Notwithstanding anything herein and for the avoidance
of doubt, there shall not be a Registration Default if, and to the extent that such Registration Statement is not permitted under applicable
law or by the Commission. The parties acknowledge and agree that damages which will result to Lender for Company’s failure to timely
file or have declared effective the Registration Statement shall be extremely difficult or impossible to establish or prove, and agree
that the payment of Liquidated Damage Penalty is a reasonable estimate of potential damages and shall constitute liquidated damages for
any breach of this paragraph. Any amounts due under this Section shall be paid by the fifth (5th) day of the month following the month
in which they accrued or, at the option of Lender, added to the principal of the Note. The legal fees associated with filing the Registration
Statement shall be paid by Company.
8.
SHAREHOLDER APPROVAL. Within sixty (60) days from the closing of the Business Combination, the Company shall use commercially
reasonable efforts to hold a special shareholder meeting seeking shareholder approval of the Transaction Documents (the “Shareholder
Approval”). If, despite the Company’s commercially reasonable efforts, the Shareholder Approval is not initially obtained,
the Company shall cause an additional shareholder meeting to be held every three (3) months thereafter until such Shareholder Approval
is obtained. Notwithstanding anything to the contrary contained in this Section 8, the Company shall have no obligation to solicit or
obtain the Shareholder Approval if Nasdaq Listing Rule 5635(d) no longer applies to the Company or would not prohibit the Lender from
acquiring shares of Class A Common Stock pursuant to Note or Warrant without receipt of such Shareholder Approval.
9.
REPRESENTATIONS AND WARRANTIES BY THE COMPANY. In order to induce Lender to enter into this Agreement and to make the Loans
provided for herein, Company represents and warrants to Lender as follows:
a.
Organization, Good Standing and Power. The Company is a corporation duly incorporated, validly existing and in good standing under
the laws of the Delaware and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its
business as it is now being conducted.
b.
Reserved.
c.
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and perform this Agreement,
the Note, the Warrants, and the Registration Rights Agreement (all such documents together with all amendments, schedules, exhibits,
annexes, supplements and related items, to each such document shall hereinafter be collectively referred to as, the “Transaction
Documents”). The execution, delivery and performance of the Transaction Documents by the Company, and the consummation by it of
the transactions contemplated in, have been duly and validly authorized by all necessary corporate action, including a vote of the shareholders,
if so required. The Transaction Documents, when executed and delivered, will constitute valid and binding obligations of the Company
enforceable against the Company in accordance with their terms, except as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally
the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.
d.
Disclosure. None of the Transaction Documents nor any other document, certificate or instrument furnished to the Lender by or
on behalf of the Company in connection with the transactions contemplated by the Transaction Documents contains any untrue statement
of a material fact or omits to state a material fact necessary in order to make the statements made herein or therein, in the light of
the circumstances under which they were made herein or therein, not misleading.
e.
Adequate Shares; Transfer Agent Instructions. The Company will at all times have authorized and reserved a sufficient number of
shares of Common Stock to provide for the exercise of the rights represented by the respective Warrants and Notes. The Company shall
issue irrevocable instructions to the transfer agent in a form acceptable to the Lender (the “TA Instructions Letter”) to
issue certificates or credit shares to the applicable balance accounts at The Depository Trust Company (“DTC”), registered
in the name of the Lender or its respective nominee(s), for the underlying shares for the Note and Warrants in such amounts as specified
from time to time by the Lender to the Company upon conversion of the Notes or exercise of the Warrants in substantially the form attached
as Exhibit D. The Company represents and warrants that no instruction other than the TA Instructions Letter referred to in this
Section will be given by the Company to its transfer agent with respect to the securities, and that the securities shall otherwise be
freely transferable on the books and records of the Company, as applicable, to the extent provided in this Agreement and the other Transaction
Documents. In the event that such sale, assignment or transfer involves the underlying shares sold, assigned or transferred pursuant
to an effective registration statement or in compliance with Rule 144, the Company shall cause its transfer agent to issue such shares
to such buyer, assignee or transferee (as the case may be) without any restrictive legend in accordance with this Agreement to the extent
permitted by applicable law. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to
Lender. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section be inadequate
and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section, that Lender shall be entitled,
in addition to all other available remedies, to seek an order and/or injunction restraining any breach and requiring immediate issuance
and transfer, without the necessity of showing economic loss and without any bond or other security being required. The Company shall
cause its counsel to issue the legal opinion referred to in the TA Instructions Letter to the Company’s transfer agent from and
after the Applicable Date to the extent permissible by law. Any fees (with respect to the transfer agent, counsel to the Company or otherwise)
associated with the issuance of such opinion or the removal of any legends on any of the securities shall be borne by the Company. “Applicable
Date” means the first date on which all of the underlying securities are eligible to be resold by the Lender pursuant to Rule 144
or an effective registration statement.
f.
Periodic Filings. The Company has filed all reports, schedules, forms, statements and other
documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file
such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the “SEC Reports”) on a timely basis or has received a
valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.
Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (“GAAP”), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments. The Company at all times will remain current in its reporting requirements
with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and to maintain its continued listing
of the Company’s Class A Common Stock on Nasdaq Capital Market or the Nasdaq Global Market, as determined by the Company.
g.
Subsequent Equity Sales. Except for the transaction contemplated by the Transaction Documents and any other transactions previously
disclosed and approved by the express written consent of the Lender, for a period of twelve (12) months from the date hereof, the Company
shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of
shares of Class A Common Stock or Common Stock Equivalents (as defined in the Note) (or a combination of units thereof) involving a Variable
Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt
or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of
Class A Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies
with the trading prices of or quotations for the shares of Class A Common Stock at any time after the initial issuance of such debt or
equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the
initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Class A Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price, or an
at-the-market offering. Any Lender shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which
remedy shall be in addition to any right to collect damages.
h.
No Defaults. No event has occurred and no condition exists which would constitute an Event of Default pursuant to this Loan Agreement.
Company is not in violation in any material respect of any term of any agreement, charter instrument, bylaw or other instrument to which
it is a party or by which it may be bound, where the violation would have a Material Adverse Effect.
i.
Taxes. All tax returns required to be filed by the Company in any jurisdiction have in fact been filed, and all taxes, assessments,
fees and other governmental charges upon the Company, or upon any of its properties, which are due and payable have been paid. Company
does not know of any proposed additional tax assessment against it. The accruals for taxes on the books of the Company for its current
fiscal period are adequate.
j.
Compliance with Law. Company (a) is not in violation of any state laws, ordinances, governmental rules or regulations to which
it is subject and (b) has not failed to obtain any licenses, permits, franchises or other governmental or environmental authorizations
necessary to the ownership of its properties or to the conduct of its business, which violation or failure might materially and adversely
affect the business, prospects, profits, properties or condition (financial or otherwise) of the Company.
k.
Consents and Approvals. Except as set forth in this Section 9(k), neither the nature of the Company or of its business or properties,
nor any relationship between the Company and any other entity or person, nor any circumstance in connection with the execution of this
Loan Agreement, is such as to require a consent, approval or authorization of, or filing, registration or qualification with, any governmental
authority on the part of the Company as a condition to the execution and delivery of this Loan Agreement and the notes and documents
contemplated herein (collectively, the “Required Approvals”). For the avoidance of doubt, compliance with Nasdaq Listing
Rule 5635(d) shall be a Required Approval. Specifically, the Company shall not effect the conversion of any of the Class A Common Stock
under the Note, or the exercise of any Warrant held by an Lender, or pay any dividend in the form of common stock, and an Lender shall
not have the right to convert any of the Class A Common Stock or exercise Warrants held by such Lender and any such conversion or exercise
shall be null and void and treated as if never made, if to the extent that after giving effect to such payment of dividend in the form
of common stock, or such conversion of the Note or exercise of such Warrant, the aggregate outstanding shares of all classes of the Company’s
common stock issuable to the Lender would exceed, when added to the previously issued shares of Class A Common Stock under the Transaction
Documents, the requirements of Nasdaq Listing Rule 5635(d) (“Nasdaq 19.99% Cap”), except that such limitation will not apply
at any time following Shareholder Approval. The date in which the Nasdaq 19.99% Cap is calculated shall be the date immediately preceding
the issuance of the securities before the issuance of the Warrant and Note.
l.
Material Adverse Effect. There are no pending or threatened claims against the Company in excess of $50,000 or alleging a class
action against the Company. There is no action, suit, audit, proceeding, investigation or arbitration (or series of related actions,
suits, proceedings, investigations or arbitrations) pending before or by any governmental authority or private arbitrator or, to the
knowledge of the Company, threatened against the Company or any property of the Company (a) challenging the validity or the enforceability
of any of this Loan Agreement, or any loan document, agreement, or instrument executed in connection herewith, or (b) which has had,
shall have or is reasonably likely to have a Material Adverse Effect. Company is not in violation of any applicable requirements of state
law which violation shall have or is likely to result in a Material Adverse Effect, or subject to or in default with respect to any final
judgment, writ, injunction, restraining order or order of any nature, decree, rule or regulation of any court or governmental authority,
in each case which shall have or is likely to have a Material Adverse Effect. Further, no other circumstances or conditions exist that
shall have or is reasonably likely to have a Material Adverse Effect on the Company. As used in this Loan Agreement, “Material
Adverse Effect” means a material adverse effect upon (aa) the business, condition (financial or otherwise), operations, performance,
properties or prospects of the Company or any guarantor, (bb) the ability of the Company or any guarantor to perform its obligations
under this Loan Agreement or any document, agreement, guaranty, or instrument executed in connection herewith, or (cc) the ability of
Lender to enforce the terms of this Loan Agreement, or any document, agreement, guaranty, or instrument executed in connection herewith.
m.
Nasdaq 20% Rule. The transaction or series of transactions under the Transaction Documents may constitute the issuance or potential
issuance by the Company of securities convertible into or exercisable for common stock equal to 20% or more of the aggregate outstanding
shares of all classes of the Company’s common stock or 20% or more of the voting power outstanding before the issuance of for less
than the Minimum Price. “Minimum Price” means a price that is the lower of: (i) the Nasdaq official closing price (as reflected
on Nasdaq.com) immediately preceding the signing of the binding agreement; or (ii) the average Nasdaq official closing price of the common
stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the binding agreement. Further, Nasdaq
shall likely conclude the Transaction Documents between the parties and a substantially similar set of transaction documents between
the Company and a third party, with a date contemporaneous hereof, shall be part of a single plan of financing and shall therefore be
aggregated for the purposes of the Nasdaq 19.99% Cap. Consequently, the Company shall seek Shareholder Approval, in accordance with Section
8 of this Agreement, prior to the issuance of securities in excess of the Nasdaq 19.99% Cap in connection with the transaction in accordance
with Nasdaq Rule 5635(d).
n.
Foreign Corrupt Practices Act. Except as otherwise disclosed in the Company’s SEC reports, neither the Company nor, to the
Company’s knowledge, any of its affiliates, directors, officers, employees, agents or other person acting on behalf of the Company
is aware of or has taken any action, directly or indirectly, that would result in a material violation by such person of the Foreign
Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation,
making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise
to pay or authorization of the payment of money, or other property, gift, promise to give, or authorization of the giving of anything
of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof
or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the Company’s knowledge, its
affiliates have conducted their businesses in material compliance with the FCPA and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.
o.
Rule 506(d) Bad Actor Disqualification Representations and Covenants.
(i)
No Disqualification Events. Neither the Company, nor any of its predecessors, affiliates, any manager, executive officer, other
officer of the Company participating in the offering, any beneficial owner (as that term is defined in Rule 13d-3 under the Exchange
Act) of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity as of the date of this Agreement
and on the Closing Dates (each, a “Company Covered Person” and, together, “Company Covered Persons”) is subject
to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to
determine (A) the identity of each person that is a Company Covered Person; and (B) whether any Company Covered Person is subject to
a Disqualification Event. The Company will comply with its disclosure obligations under Rule 506(e).
(ii)
Other Covered Persons. The Company is not aware of any person (other than any Company Covered Person) who has been or will be
paid (directly or indirectly) remuneration in connection with the purchase and sale of the Notes, the Warrants and/or the Commitment
Shares who is subject to a Disqualification Event (each, an “Other Covered Person”).
(iii)
Reasonable Notification Procedures. With respect to each Company Covered Person, the Company has established procedures reasonably
designed to ensure that the Company receives notice from each such Company Covered Person of (A) any Disqualification Event relating
to that Company Covered Person, and (B) any event that would, with the passage of time, become a Disqualification Event relating to that
Company Covered Person; in each case occurring up to and including the Closing Dates.
(iv)
Notice of Disqualification Events. The Company will notify the Lender immediately in writing upon becoming aware of (A) any Disqualification
Event relating to any Company Covered Person and (B) any event that would, with the passage of time, become a Disqualification Event
relating to any Company Covered Person and/or Other Covered Person.
p.
Sarbanes-Oxley; Internal Accounting Controls. Except as set forth in the SEC Reports, the
Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective
as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as
of the date hereof and as of the Closing Dates. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset
accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and
(iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures
to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s
certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as
of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation
Date”). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its subsidiaries.
q.
Insurance. Except as set forth in the SEC Reports, the Company is insured by insurers of
recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the business in
which it is engaged; the Company has not been refused any coverage sought or applied for; and the Company does not have any reason to
believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect on the Company.
r.
Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’
employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.
s.
Dilutive Effect. The Company understands and
acknowledges that the number of Conversion Shares issuable upon conversion of the Notes, pursuant to the terms thereof, will increase
in certain circumstances. The Company further acknowledges that its obligations to issue Conversion Shares pursuant to the terms of the
Notes in accordance with this Agreement and the Notes and to issue Warrant Shares upon exercise of the Warrants in accordance with this
Agreement and the Warrants are, in each case, absolute and unconditional regardless of the dilutive effect that any such issuances may
have on the percentage ownership interests of other stockholders of the Company.
t.
Application of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary action,
if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provisions under the Company’s certificate of incorporation, as amended,
or the laws of the jurisdiction of its formation that are or could become applicable to the Lender as a result of the transactions contemplated
by this Agreement and/or the other Transaction Documents, including, without limitation, the Company’s issuance of the Securities
and the Lender’s ownership of the Securities. The Company has not adopted a stockholder rights plan or similar arrangement relating
to accumulations of beneficial ownership of Class A Common Stock or a change in control of the Company.
u.
DTC Eligible. The Class A Common Stock is DTC eligible and DTC has not placed a “freeze” or a “chill”
on the Class A Common Stock and the Company has no reason to believe that DTC has any intention to make the Class A Common Stock not
DTC eligible, or place a “freeze” or “chill” on the Class A Common Stock.
v.
Listing and Maintenance Requirements. The Class A Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Class A Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof,
received notice from any Trading Market on which the Class A Common Stock are or have been listed or quoted to the effect that the Company
is not in compliance with the listing or maintenance requirements of such Trading Market. The Class A Common Stock is eligible for quotation
on the Principal Market and the Company has no reason to believe that the Principal Market has any intention of delisting the Class A
Common Stock from the Principal Market. The issuance and sale of the Securities hereunder does not contravene the rules and regulations
of the Trading Market. All Underlying Shares have been approved, if so required, for listing or quotation on the Trading Market, subject
only to notice of issuance.
w.
No General Solicitation. Neither the Company, nor any of its affiliates, nor, to the knowledge of the Company, any Person acting
on its behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection
with the offer or sale of the underlying securities.
x.
Off-Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated
or other off-balance sheet entity that is required to be disclosed by the Company in its Exchange Act filings and is not so disclosed
or that otherwise would be reasonably likely to have a Material Adverse Effect.
y.
Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted
at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively,
the “Money Laundering Laws”), and no Action or Proceeding by or before
any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money
Laundering Laws is pending or, to the knowledge of the Company or any subsidiary, threatened.
z.
Environmental Laws. The Company and its Subsidiaries, to the best of the Company’s
knowledge, (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health
or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to
emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes
(collectively, “Hazardous Materials”) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.
10.
REPRESENTATIONS AND WARRANTIES BY LENDER. Lender, by the acceptance of this Note, represents and warrants to Company as follows:
a.
Lender is acquiring the Notes with
the intent to hold as an investment and not with a view of distribution.
b.
Lender is an “accredited investor”
within the definition contained in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”), and is
acquiring the Notes for its own account, for investment, and not with a view to, or for sale in connection with, the distribution thereof
or of any interest therein. Lender has adequate net worth and means of providing for its current needs and contingencies and is able
to sustain a complete loss of the investment in the Notes, and has no need for liquidity in such investment. Lender, itself or through
its officers, employees or agents, has sufficient knowledge and experience in financial and business matters to be capable of evaluating
the merits and risks of an investment such as an investment in the Securities, and Lender, either alone or through its officers, employees
or agents, has evaluated the merits and risks of the investment in the Notes.
c.
Lender acknowledges and agrees that
it is purchasing the Notes hereunder based upon its own inspection, examination and determination with respect thereto as to all matters,
and without reliance upon any express or implied representations or warranties of any nature, whether in writing, orally or otherwise,
made by or on behalf of or imputed to the Company.
11.
LIQUIDATED DAMAGES.
a.
In the event of a Registration Default, the Company hereby agrees to pay to the Lender Liquidated Damage Penalty as set forth in Section
7 until the Registration Statement takes effective. Following the cure of all Registration Defaults relating to any particular registrable
Securities, Liquidated Damages shall cease to accrue; provided, however, that, if after Liquidated Damages have ceased to accrue, a different
Registration Default occurs, Liquidated Damages shall again accrue pursuant to the foregoing provisions. Any amounts due under this Section
shall be paid by the fifth (5th) day of the month following the month in which they accrued.
b.
The Company and Lender hereto acknowledge and agree
that the sums payable as Liquidated Damages under subsection 11(a) and Section 12 below shall constitute liquidated damages and
not penalties and are in addition to all other rights of the Lender, including the right to call a default under the Loan Agreement.
The parties further acknowledge that (i) the amount of loss or damages likely to be incurred is incapable or is difficult to precisely
estimate, (ii) the amounts specified in such subsections bear a reasonable relationship to, and are not plainly or grossly disproportionate
to, the probable loss likely to be incurred in connection with any failure by the Company to obtain or maintain the effectiveness of
a registration statement, (iii) one of the reasons for the Company and the Lender reaching an agreement as to such amounts was the uncertainty
and cost of litigation regarding the question of actual damages, and (iv) the Company and the Lender are sophisticated business parties
and have been represented by sophisticated and able legal counsel and negotiated this Agreement at arm’s length.
12.
ORDINARY SHARE ISSUANCE. Upon receipt by the Company of a written request from Lender to convert any amount due under any
Note or to exercise any portion of any Warrant, subject to any limitations on conversion or exercise contained in any Note and/or Warrant,
the Company shall have three (3) business days (“Delivery Date”) to issue the Class A Common Stock rightfully listed in such
request. If the Company fails to timely deliver the shares, the Company shall pay to Lender in immediately available funds $1,000.00
per business day past the Delivery Date that the shares are actually issued. Any amounts due under this Section shall be paid by the
fifth (5th) day of the month following the month in which they accrued or, at the option of Lender, may be added to the principal
under any Note. The Company agrees that the right to convert the Note or exercise its Warrants is a valuable right to Lender and a material
consideration of it entering this Agreement. The parties agree that it would be impracticable and extremely difficult to ascertain the
amount of actual damages caused by a failure of the Company to timely deliver shares as required hereby. Therefore, the parties agree
that the foregoing liquidated damages provision represents reasonable compensation for the loss which would be incurred by the Lender
due to any such breach. The parties agree that this Section is not intended to in any way limit Lender’s right to pursue other
remedies, including actual damages and/or equitable relief.
13.
EVENTS OF DEFAULT. An event of default will occur if any of the following circumstances occur (each an “Event of Default”):
a.
Any representation or warranty made by Company in this Agreement or in connection with any Warrant or Note, or in any financial statement,
or any other statement furnished by Company to Lender is untrue in any material respect at the time when made or becomes untrue;
b.
Default by Company in the observance or performance of any other covenant or agreement contained in this Agreement;
c.
Default by Company under the terms of any Note, Warrant, Registration Agreement or any other third party note or warrant that exceeds
a value of $500,000;
d.
Filing by Company of a voluntary petition in bankruptcy seeking reorganization, arrangement or readjustment of debts, or any other relief
under the Bankruptcy Code as amended or under any other insolvency act or law, state or federal, now or hereafter existing;
e.
Filing of an involuntary petition against Company in bankruptcy seeking reorganization, arrangement or readjustment of debts, or any
other relief under the Bankruptcy Code as amended, or under any other insolvency act or law, state or federal, now or hereafter existing,
and the continuance thereof for sixty (60) days undismissed, unbonded or undischarged;
f.
Company liquidates, transfers, sells or assigns substantially its assets or elects to wind down its operations or dissolve;
g.
The Company fails to maintain the TA Instruction Letter, file with the Company’s transfer agent, or update the TA Instruction Letter
to increase the reserve shares as needed, along with a reserve of Class A Common Stock sufficient to satisfy the Notes and Warrants based
on a then hypothetical conversion scenario per the terms of the Note and the Warrant Shares;
h.
The Company fails to maintain DTC or DWAC eligibility;
i.
The Company fails to stay current in its SEC reporting obligations or maintain its continued listing of the Company’s Class A Common
Stock on Nasdaq Global Market or Nasdaq Capital Market;
j.
The Company fails to deliver Lender the Class A Common Stock rightfully listed in any Conversion Notice or any Warrants Exercise Notice
within three (3) business days of receipt of such notice(s);
k.
The Company breaches any other agreement it has with Lender or his assigns;
l.
The Company interferes with Lender’s or its assigns’ efforts to remove the restrictive legend from the Class A Common Stock
issued as a result of conversion of any Note when Lender or his assign has provided a reasonable attorney opinion letter from a reputable
law firm opining that the shares are eligible to have the legend removed pursuant to Rule 144 or otherwise;
m.
The occurrence of a Registration Default; and
n.
The Company issues, grants or sells an additional issuance on contrast to Section 9(g) of this Agreement.
14.
REMEDIES. (i) There will be no cure period available for the Event of Default as defined in Section 13(d), 13(e) and 13(m);
or (ii) upon the occurrence of any other Event of Default as defined above, and provided such Event of Default has not been cured by
the Company within ten (10) business days after written notice of the occurrence of such Event of Default, the principal and any accrued
interest of the Note will be due immediately, and Lender shall have all of the rights and remedies provided by applicable law and equity.
In the event of a default under Section 13(m), the sole penalty shall be as provided for in Section 11 hereof and as provided in the
Note. To the extent permitted by law, Company waives any rights to presentment, demand, protest, or notice of any kind in connection
with this Agreement, any Warrant and/or any Note. No failure or delay on the part either party in exercising any right, power, or privilege
hereunder or thereunder will preclude any other or further exercise thereof or the exercise of any other right, power, or privilege.
The rights and remedies provided herein are cumulative and not exclusive of any other rights or remedies provided at law or in equity.
Following the closing of the Business Combination, in the event Lender shall refer this Agreement to an attorney to enforce the terms
hereof, the Company agrees to pay all the costs and expenses incurred in attempting or effecting the enforcement of the Lender’s
rights, including reasonable attorney’s fees, whether or not suit is instituted.
15.
PUBLIC INFORMATION. After the closing of
the Business Combination, except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide the Lender or its
agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information,
unless prior thereto the Lender shall have consented to the receipt of such information and agreed with the Company to keep such information
confidential. The Company understands and confirms that the Lender shall be relying on the foregoing covenant in effecting transactions
in securities of the Company. To the extent that the Company delivers any material, non-public information
to a Lender without such Lender’s consent, the Company hereby covenants and agrees that such Lender shall not have any duty of
confidentiality to the Company, any of its subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates,
or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not
to trade on the basis of, such material, non-public information, provided that the Lender
shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The
Company understands and confirms that the Lender shall be relying on the foregoing covenant in effecting transactions in securities of
the Company.
16.
INDEMNIFICATION OF LENDER. Subject to the
provisions of this Section 16, the Company will indemnify and hold the Lender and its directors, officers, shareholders, members, partners,
employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title), each Person who controls such Lender (within the meaning of Section 15 of the Securities Act and Section
20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with
a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling
persons (each, a “Lender Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, as incurred, arising out of or relating to (i) any untrue or alleged
untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment
or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto,
in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that such
untrue statements or omissions are based solely upon information regarding such Lender Party furnished in writing to the Company by such
Lender Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the Exchange
Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall be brought against
any Lender Party in respect of which indemnity may be sought pursuant to this Agreement, such Lender Party shall promptly notify the
Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Lender Party. Any Lender Party shall have the right to employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Lender Party except to the extent that (x) the employment
thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable period of time to assume
such defense and to employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material conflict on any material
issue between the position of the Company and the position of such Lender Party, in which case the Company shall be responsible for the
reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Lender Party under this
Agreement (1) for any settlement by a Lender Party effected without the Company’s prior written consent, which shall not be unreasonably
withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Lender
Party’s breach of any of the representations, warranties, covenants or agreements made by such Lender Party in this Agreement or
in the other Transaction Documents. The indemnification required by this Section 16 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Lender Party against the Company or others and any liabilities
the Company may be subject to pursuant to
17.
FORM D; BLUE SKY FILINGS. The Company agrees
to timely file a Form D with respect to the securities as required under Regulation D and to provide a copy thereof, promptly upon request
of any Lender. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption
for, or to qualify the Securities for, sale to the Lender at the applicable Closing under applicable securities or “Blue Sky”
laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Lender.
18.
NOTICE. Any and all notices, demands, advance requests or other communications required or desired to be given hereunder by any
party shall be in writing and shall be validly given or made to another party if (i) personally served, (ii) sent by email on the date
such email is sent (provided confirmation of such email being sent is provided upon request) (iii) deposited in the United States mail,
postage prepaid, return receipt requested, or (iv) by facsimile with confirmation receipt. Notice hereunder is to be given as follows:
|
|
If to the Company:
|
|
|
|
|
|
Deep
Medicine Acquisition Corp. |
|
|
1096
Keeler Avenue |
|
|
Berkeley,
CA 94708 |
|
|
Email:
Humphrey.polanen@gmail.com |
|
|
Attn:
Humphrey P. Polanen |
|
|
|
|
If to the Lender: |
|
|
|
|
|
|
Finuvia,
LLC |
|
|
1221
College Park Dr. Suite 116 |
|
|
Dover,
DE 19904 |
|
|
Email:
Ricky@pmibusiness.com |
|
|
Attn:
Weiheng Cai |
19.
USURY. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at
any time hereafter in force, in connection with any action or proceeding that may be brought by any Lender in order to enforce any right
or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any Transaction Document, it is
expressly agreed and provided that the total liability of the Company under the Transaction Documents for payments in the nature of interest
shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum
Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default
interest, or both of them, when aggregated with any other sums in the nature of interest that the Company may be obligated to pay under
the Transaction Documents exceed such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable
to the Transaction Documents is increased or decreased by statute or any official governmental action subsequent to the date hereof,
the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from the effective
date thereof forward, unless such application is precluded by applicable law. If under any circumstances whatsoever, interest in excess
of the Maximum Rate is paid by the Company to any Lender with respect to indebtedness evidenced by the Transaction Documents, such excess
shall be applied by such Lender to the unpaid principal balance of any such indebtedness or be refunded to the Company, the manner of
handling such excess to be at such Lender’s election.
20.
GENERAL PROVISIONS. All representations and warranties made in the Transaction Documents shall survive the execution and delivery
of this Agreement and the making of any Loans hereunder. This Agreement will be binding upon and inure to the benefit of Company and
Lender, their respective successors and assigns.
21.
ENTIRE AGREEMENT. The Transaction Documents contain the entire agreement of the parties and supersedes and replaces all prior
discussions, negotiations and representations of the parties. No party shall rely upon any oral representations in entering into this
agreement, such oral representations, if any, being expressly denied by the party to whom they are attributed and it being the intention
of the parties to limit the terms of this Agreement to those matters contained herein in writing. However, the incorporated Note shall
be deemed controlling at all times with regards to any inconsistent or changed terms or amendments contained therein.
22.
BINDING EFFECT. This agreement is binding upon and inures to the benefit of the parties hereto, their heirs, personal representatives,
successors and assigns. Lender may assign their rights hereunder without prior permission from the Company. The Company may not assign
their rights or obligations hereunder without the express written consent of the Lender, which may be withheld at its discretion.
23.
GOVERNING LAW AND CONSENT TO JURISDICTION. Except as other otherwise provided herein, this Agreement shall be governed by
and construed in accordance with the laws of the State of Nevada without regard to conflict of law provisions. Each of the parties to
this Agreement irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the courts of the
State of Florida and of the United States District Court of the Southern District of Florida, and any appellate court from any thereof,
in any action or proceeding arising out of or relating to this Agreement, or for the recognition or enforcement of any judgment, and
each of the parties hereto irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be
heard and determined in such Florida State court or, to the fullest extent permitted by applicable law, in such federal court. Each of
the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by law. The Company further waives any objection to venue in any such action
or proceeding on the basis of inconvenient forum. The Company agrees that any action on or proceeding brought against the Lender shall
only be brought in such courts. Notwithstanding anything to the contrary above, Section 30 of this Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware without regard to conflict of law provisions.
24.
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.
25.
ATTORNEYS FEES. Following the Business Combination, in the event the Lender hereof shall refer this Agreement to an attorney
to enforce the terms hereof, the Company agrees to pay all the costs and expenses incurred in attempting or effecting the enforcement
of the Lender’s rights, including reasonable attorney’s fees, whether or not suit is instituted.
26.
AMENDMENT. The terms of this Agreement may not be amended, modified, or eliminated without written consent of the parties.
27.
SEVERABILITY. Every provision of this Agreement is intended to be severable. If any term or provision thereof is illegal or
invalid for any reason whatsoever, such illegality or invalidity shall not affect the validity or legality of the remainder of this Agreement.
28.
CONSTRUCTION. Section and paragraph headings are for convenience only and do not affect the meaning or interpretation of this
Agreement. No rule of construction or interpretation that disfavors the party drafting this Agreement or any of its provisions will apply
to the interpretation of this Agreement. Instead, this Agreement will be interpreted according to the fair meaning of its terms.
29.
FURTHER ASSURANCES. Each party hereto agrees to do all things, including execute, acknowledge and/or deliver any documents
which may be reasonably necessary, appropriate or desirable to effectuate the transactions contemplated herein pursuant to terms and
conditions of this Agreement.
30.
WAIVER AGAINST TRUST. Reference is made to the final prospectus of SPAC, dated as of October 26, 2021 and filed with the SEC
(File No. 333-260515) on October 28, 2021 (the “Prospectus”). Lender hereby represents and warrants that it has read the
Prospectus and understands that SPAC has established a trust account (the “Trust Account”) containing the proceeds of its
initial public offering (the “IPO”) and the overallotment securities acquired by its underwriters and from certain private
placements occurring simultaneously with the IPO (including interest accrued from time to time thereon) for the benefit of SPAC’s
public stockholders (including overallotment shares acquired by SPAC’s underwriters, the “Public Stockholders”), and
that, except as otherwise described in the Prospectus, SPAC may disburse monies from the Trust Account only: (a) to the Public Stockholders
in the event they elect to redeem their SPAC shares in connection with the consummation of SPAC’s initial business combination
(as such term is used in the Prospectus) (the “Business Combination”) or in connection with an extension of its deadline
to consummate a Business Combination, (b) to the Public Stockholders if SPAC fails to consummate a Business Combination within twelve
(12) months after the closing of the IPO, subject to extension in accordance with SPAC’s organizational documents, (c) with respect
to any interest earned on the amounts held in the Trust Account, amounts necessary to pay for any taxes and up to $50,000 in dissolution
expenses or (d) to SPAC after or concurrently with the consummation of a Business Combination. For and in consideration of SPAC entering
into this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Lender
hereby agrees on behalf of itself and its affiliates that, notwithstanding anything to the contrary in this Agreement, neither Lender
nor any of its affiliates do now or shall at any time hereafter have any right, title, interest or claim of any kind in or to any monies
in the Trust Account or distributions therefrom, or make any claim against the Trust Account (including any distributions therefrom),
regardless of whether such claim arises as a result of, in connection with or relating in any way to, this Agreement or any proposed
or actual business relationship between SPAC or its Representatives, on the one hand, and Lender or its Representatives, on the other
hand, or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other theory of legal liability
(collectively, the “Released Claims”). Lender on behalf of itself and its affiliates hereby irrevocably waives any Released
Claims that Lender or any of its affiliates may have against the Trust Account (including any distributions therefrom) now or in the
future as a result of, or arising out of, any negotiations, contracts or agreements with SPAC or its Representatives and will not seek
recourse against the Trust Account (including any distributions therefrom) for any reason whatsoever (including for an alleged breach
of this Agreement or any other agreement with SPAC or its affiliates). Lender agrees and acknowledges that such irrevocable waiver is
material to this Agreement and specifically relied upon by SPAC and its affiliates to induce SPAC to enter in this Agreement, and Lender
further intends and understands such waiver to be valid, binding and enforceable against Lender and each of its affiliates under applicable
law. To the extent Lender or any of its affiliates commences any action or proceeding based upon, in connection with, relating to or
arising out of any matter relating to SPAC or its Representatives, which proceeding seeks, in whole or in part, monetary relief against
SPAC or its Representatives, Lender hereby acknowledges and agrees that Lender’s and its affiliates’ sole remedy shall be
against funds held outside of the Trust Account and that such claim shall not permit Lender or its affiliates (or any person claiming
on any of their behalves or in lieu of any of them) to have any claim against the Trust Account (including any distributions therefrom)
or any amounts contained therein. In the event Lender or any of its affiliates commences any action or proceeding based upon, in connection
with, relating to or arising out of any matter relating to SPAC or its Representatives, which proceeding seeks, in whole or in part,
relief against the Trust Account (including any distributions therefrom) or the Public Stockholders, whether in the form of money damages
or injunctive relief, SPAC and its Representatives, as applicable, shall be entitled to recover from Lender and its affiliates the associated
legal fees and costs in connection with any such action, in the event SPAC or its Representatives, as applicable, prevails in such action
or proceeding. For the avoidance of doubt, the provisions of this paragraph 8 shall not restrict the Lender in its capacity as a Public
Stockholder, if applicable, from redeeming any shares of SPAC that it owns in accordance with SPAC’s organizational documents and
the Prospectus.
IN
WITNESS WHEREOF, the parties hereto enter into this Loan Agreement which is effective as of the date first written.
Company: |
|
Lender: |
|
|
|
|
|
Deep
Medicine Acquisition Corp. |
|
Finuvia,
LLC |
|
|
|
|
|
By:
|
/s/ Humphrey P. Polanen |
|
By:
|
/s/
Weiheng Cai |
Name:
|
Humphrey
P. Polanen |
|
Name:
|
Weiheng
Cai |
Title:
|
Chief
Executive Officer |
|
Title:
|
Manager |
EXHIBIT
A
CONVERTIBLE
NOTE
[See
Attached]
EXHIBIT
B
WARRANT
AGREEMENT
[See
Attached]
EXHIBIT
C
REGISTRATION
RIGHTS AGREEMENT
[See
Attached]
EXHIBIT
D
TA
INSTRUCTION LETTER
[See
Attached]
Exhibit
10.3
REGISTRATION
RIGHTS AGREEMENT
This
Registration Rights Agreement (this “Agreement”) is made and entered into as of , 20 , by and among TruGolf
Inc., a Delaware corporation (the “Company”) and (the “Investor”).
WHEREAS,
the Investor has, pursuant to that certain Loan Agreement, dated as of November 2, 2023, between the Company and the Investor
(the “Loan Agreement”), agreed to purchase a certain convertible note from the Company (the “Note”),
subject to the terms and conditions set forth therein and were granted warrants from the Company (the “Warrant”),
subject to the terms and conditions set forth therein; and
WHEREAS,
it is a condition to the closing (the “Closing”) of the transactions contemplated by the Loan Agreement that
the Company and the Investor enter into this Agreement at or prior to the Closing in order to grant the Investor certain registration
rights as set forth herein.
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and the Investor agree as follows:
1.
Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Loan Agreement shall
have the meanings given such terms in the Loan Agreement. As used in this Agreement, the following terms shall have the respective meanings
set forth in this Section 1:
“Affiliate”
of any Person shall mean any other Person directly or indirectly controlling or controlled by or under direct or indirect common control
with such Person. For purposes of this definition, “control” when used with respect to any Person has the meaning specified
in Rule 12b-2 under the Exchange Act; and the terms “controlling” and “controlled” have meanings correlative
to the foregoing.
“Available”
means, with respect to the Registration Statement, that such Registration Statement does not contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading, such that the Registration Statement will be available for the resale of
Registrable Securities.
“Business
Day” means a day that is a Monday, Tuesday, Wednesday, Thursday or Friday and is not a day on which banking institutions
in New York, New York generally are authorized or obligated by law, regulation or executive order to close.
“Commission”
means the Securities and Exchange Commission or any other federal agency then administering the Securities Act or Exchange Act.
“Effective
Date” means the time and date that the Registration Statement filed pursuant to Section 2(a) is first declared effective
by the Commission or otherwise becomes effective.
“Effectiveness
Date” means the 75th day following the Filing Date.
“Effectiveness
Period” has the meaning set forth in Section 2(a).
“Electing
Holders” means the Holder that hold no less than a majority of the Registrable Securities then held by the Holders.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended.
“Filing
Date” means the 30th day following the Closing.
“Freely
Tradable” means, with respect to any security, a security that is eligible to be sold by the Holder thereof without any
volume or manner of sale restrictions under the Securities Act pursuant to Rule 144.
“Holder”
or “Holders” means (i) the Investor and (ii) permitted assignees of the Investor who are assigned rights hereunder,
in each case to the extent that they continue to hold Registrable Securities.
“Indemnified
Party” has the meaning set forth in Section 5(c).
“Indemnifying
Party” has the meaning set forth in Section 5(c).
“Losses”
has the meaning set forth in Section 5(a).
“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Plan
of Distribution” means the plan of distribution in substantially the form attached hereto as Annex A.
“Proceeding”
means a pending action, claim, suit, or proceeding (including, without limitation, an investigation or partial proceeding, such as a
deposition) or investigation known to the Company to be threatened.
“Prospectus”
means the prospectus included in the Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under
the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion
of the Registrable Securities covered by the Registration Statement, and all other amendments and supplements to the Prospectus, including
post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.
“Questionnaire”
has the meaning set forth in Section 3(k).
“Registrable
Securities” means (i) the Common Stock issuable or issued upon conversion of the Note (including any Make-Whole Shares,
as defined in the Note), (ii) the Common Stock issuable upon exercise of the Warrants, and (iii) any securities issued (or issuable upon
the conversion or exercise of any warrant, right or other security) that is issued as a dividend, stock split, recapitalization or other
distribution with respect to, or in exchange for, or in replacement of, the securities referenced in clause (i) and (ii) (without giving
effect to any election by the Company therein), above or this clause (iii) at the “floor” price set forth in the Notes and
Warrants; provided, however, that the term “Registrable Securities” shall exclude in all cases
any securities (1) sold or exchanged by a Person pursuant to an effective registration statement under the Act or in compliance with
Rule 144, (2) that are Freely Tradable (it being understood that for purposes of determining eligibility for resale under clause (2)
of this proviso, no securities held by any Holder shall be considered Freely Tradable to the extent such Holder reasonably determines
that it is an Affiliate of the Company) or (3) that shall have ceased to be outstanding.
“Registration
Default” has the meaning set forth in Section 2(b).
“Registration
Statement” means the registration statement in the form required to register the resale of the Registrable Securities,
and including the Prospectus, amendments and supplements to each such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration
statement.
“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
“Rule
405” means Rule 405 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
“Rule
433” means Rule 433 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
“Securities
Act” means the Securities Act of 1933, as amended.
“Trading
Day” means a day during which trading in the Common Stock generally occurs.
“Trading
Market” means the principal national securities exchange on which the Common Stock is listed.
“Use
Notice” has the meaning set forth in Section 3(j).
2.
Registration.
(a)
On or prior to the Filing Date, the Company will use commercially reasonable efforts to prepare and file with the Commission the Registration
Statement covering the resale of all Registrable Securities. The Registration Statement (i) shall be on Form S-1 or Form S-3 and (ii)
shall contain (except if otherwise requested by the Electing Holders or required pursuant to written comments received from the Commission
upon a review of such Registration Statement) the Plan of Distribution. The Company will use its commercially reasonable efforts to cause
the Registration Statement to be declared effective or otherwise to become effective under the Securities Act as soon as possible but,
in any event, no later than the Effectiveness Date, and will use their commercially reasonable efforts to keep the Registration Statement
(or a replacement Registration Statement) continuously effective under the Securities Act until the registration rights under this Agreement
terminate in accordance with Section 2(d) (the “Effectiveness Period”).
(b)
If: (i) the Registration Statement is not filed on or prior to its Filing Date, (ii) the Registration Statement is not declared effective
by the Commission or does not otherwise become effective on or prior to its required Effectiveness Date or (iii) after its Effective
Date, such Registration Statement ceases for any reason to be effective as to all Registrable Securities to which it is required to cover
at any time prior to the expiration of the Effectiveness Period (any such failure or breach being referred to as a “Registration
Default”), such a Registration Default shall be subject to the Liquidated Damages Penalty in accordance with the terms
and conditions of the Loan Agreement.
(c)
With the exception for those certain registration rights agreements currently effective with the Company’s founders, the Company
shall not, from the date hereof until the Effective Date of the Registration Statement, prepare and file with the Commission a registration
statement relating to an offering of any of its securities for its own account or the account of others under the Securities Act
The
registration rights granted under this Section 2 shall automatically terminate upon the earlier of (i) such time as there are no outstanding
Registrable Securities and (ii) ________ [●], 2030
3.
Registration Procedures.
The
procedures to be followed by the Company and each selling Holder, and the respective rights and obligations of the Company and such Holders,
with respect to the preparation, filing and effectiveness of the Registration Statement, and the distribution of Registrable Securities
pursuant thereto, are as follows:
(a)
The Company will, at least five (5) Trading Days prior to the filing of the Registration Statement or any related Prospectus or any amendment
or supplement thereto (other than any amendment or supplement made through the incorporation by reference of ordinary course Exchange
Act filings), (i) furnish to the Holders copies of all such documents proposed to be filed, which documents will be subject to the reasonable
review of such Holders and (ii) use its commercially reasonable efforts to address in each such document when so filed with the Commission
such comments as the Holders reasonably shall propose.
(b)
The Company will use commercially reasonable efforts to (i) prepare and file with the Commission such amendments, including post-effective
amendments, and supplements to the Registration Statement and the Prospectus used in connection therewith as may be necessary under applicable
law with respect to the disposition of all Registrable Securities covered by such Registration Statement continuously effective as to
the applicable Registrable Securities for its Effectiveness Period and prepare; (ii) cause the related Prospectus to be amended or supplemented
by any required Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424; and (iii) respond as promptly
as reasonably possible to any comments received from the Commission with respect to the Registration Statement or any amendment thereto
and, as promptly as reasonably possible provide the Holders true and complete copies of all correspondence from and to the Commission
relating to such Registration Statement that pertains to the Holders as selling securityholders but not any comments that would result
in the disclosure to the Holders of material and non-public information concerning the Company.
(c)
The Company will comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect to the Registration
Statement and the disposition of all Registrable Securities covered by the Registration Statement.
(d)
The Company will notify the Holders as promptly as reasonably possible (i) of the issuance by the Commission of any stop order suspending
the effectiveness of the Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings
for that purpose; and (ii) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose.
(e)
The Company will use commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of the Registration
Statement, at the earliest practicable moment.
(f)
During the Effectiveness Period, the Company will furnish to each Holder, without charge, at least one conformed copy of the Registration
Statement and each amendment thereto and all exhibits to the extent requested by such Person (including those incorporated by reference)
promptly after the filing of such documents with the Commission; provided, that the Company will not have any obligation to provide
any document pursuant to this clause that is available on the EDGAR system.
(g)
The Company will promptly deliver to each Holder, without charge, as many copies of each Prospectus or Prospectuses (other than any amendment
or supplement made through the incorporation by reference of ordinary course Exchange Act filings) as such Persons may reasonably request
during the Effectiveness Period. The Company consents to the use of such Prospectus and each amendment or supplement thereto by each
of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment
or supplement thereto in accordance with this Agreement.
(h)
The Company will, prior to any public offering of Registrable Securities, use commercially reasonable efforts to register or qualify
or cooperate with the selling Holders in connection with the registration or qualification (or exemption from such registration or qualification)
of such Registrable Securities for offer and sale under the applicable state securities or blue sky laws of those jurisdictions within
the United States as any Holder reasonably requests in writing to keep each such registration or qualification (or exemption therefrom)
effective during the Effectiveness Period and use its commercially reasonable efforts to do any and all other acts or things necessary
or advisable to enable the disposition in such jurisdictions of the Registrable Securities covered by the Registration Statement; provided,
that the Company will not be required to (i) qualify generally to do business or as a dealer in securities in any jurisdiction where
it is not then so qualified or (ii) take any action which would subject the Company to general service of process or any material tax
in any such jurisdiction where it is not then so subject.
(i)
The Company will cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable
Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates shall be free of all restrictive
legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may request
in writing. In connection therewith, if required by the Company’s transfer agent, the Company will promptly after the effectiveness
of the Registration Statement cause an opinion of counsel as to the effectiveness of the Registration Statement to be delivered to its
transfer agent when and as required by such transfer agent from time to time, together with any other authorizations, certificates and
directions required by the transfer agent which authorize and direct the transfer agent to issue such Registrable Securities without
legend upon sale by the holder of such shares of Registrable Securities under the Registration Statement.
(j)
The Company will use commercially reasonable efforts to prepare such supplements or amendments, including a post-effective amendment,
if required by applicable law, to the Registration Statement and file any other required document so that such Registration Statement
will be Available at all times during the Effectiveness Period. No later than 8:00 p.m. (Eastern Time) on any Trading Day on which the
Company receives a written notice (a “Use Notice”) prior to 2:00 p.m. (Eastern Time) on such Trading Day (or
if such request is received after 2:00 p.m. (Eastern Time), no later than 8:00 p.m. (Eastern Time) on the following Trading Day) from
a Holder that such Holder intends to use the Registration Statement to resell Registrable Securities, the Company will provide written
confirmation to such Holder that the applicable Registration Statement is Available.
(k)
Notwithstanding any other provision of the Agreement, no Holder of Registrable Securities may include any of its Registrable Securities
in the Registration Statement pursuant to this Agreement unless the Holder furnishes to the Company a completed questionnaire substantially
in the form of Exhibit A (the “Questionnaire”) for use in connection with the Registration Statement prior
to the filing of the Registration Statement; provided, however, Investor shall not be required to furnish a Questionnaire
in connection with the Registration Statement if such Investor owns Notes or Warrants initially purchased by such Investor at the Closing
as of the initial Filing Date. Each Holder who intends to include any of its Registrable Securities in the Registration Statement shall
promptly furnish the Company in writing such other information as the Company may reasonably request in writing.
4.
Registration Expenses. All fees and expenses incident to the Company’s performance of or compliance with their
obligations under this Agreement (excluding any underwriting discounts and selling commissions, but including all legal fees and expenses
of one legal counsel to the Holders) shall be borne by the Company whether or not any Registrable Securities are sold pursuant to the
Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration
and filing fees (including, without limitation, fees and expenses (A) with respect to filings required to be made with the Trading Market,
and (B) in compliance with applicable state securities or blue sky laws), (ii) printing expenses (including, without limitation, expenses
of printing certificates for Registrable Securities and of printing prospectuses if the printing of prospectuses is reasonably requested
by the holders of a majority of the Registrable Securities included in the Registration Statement), (iii) messenger, telephone and delivery
expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such
insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions
contemplated by this Agreement. In addition, the Company shall be responsible for all of their internal expenses incurred in connection
with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of
their officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred
in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. For the avoidance of doubt,
each Holder shall pay all underwriting and placement discounts and commissions, agency and placement fees, brokers’ commissions
and transfer taxes, if any, relating to the sale or disposition of such Holder’s Registrable Securities.
5.
Indemnification.
(a)
Indemnification by the Company. The Company will, notwithstanding any termination of this Agreement, jointly and severally, indemnify
and hold harmless each Holder and each underwriter, broker-dealer or selling agent, if any, which facilitates the disposition of Registrable
Securities, the officers, directors, agents, partners, members, stockholders and employees of each of them, each Person who controls
any such Holder, underwriter, broker-dealer or selling agent (within the meaning of Section 15 of the Securities Act or Section 20 of
the Exchange Act) and the officers, directors, agents and employees of each such controlling Person, to the fullest extent permitted
by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable
costs of preparation and reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred,
arising out of or relating to any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any
Prospectus or any form of prospectus (including, without limitation, any “issuer free writing prospectus” as defined in Rule
433) or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus
or form of prospectus (including, without limitation, any “issuer free writing prospectus” as defined in Rule 433) or supplement
thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that
such Losses arise out of or are based upon any untrue statements, alleged untrue statements, omissions or alleged omissions that are
based solely upon information regarding such Holder, underwriter, broker-dealer or selling agent furnished in writing to the Company
by such Person expressly for use therein pursuant to Section 3(k) The Company shall notify the Holders promptly of the institution, threat
or assertion of any Proceeding of which the Company is aware in connection with the transactions contemplated by this Agreement.
(b)
Indemnification by Holders. Each Holder shall, notwithstanding any termination of this Agreement, severally and not jointly, indemnify
and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling
Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising solely out of or based
solely upon any untrue statement of a material fact contained in the Registration Statement, any Prospectus, or any form of prospectus
(including, without limitation, any “issuer free writing prospectus” as defined in Rule 433), or in any amendment or supplement
thereto, or arising solely out of or based solely upon any omission of a material fact required to be stated therein or necessary to
make the statements therein (in the case of any Prospectus, or any form of prospectus (including, without limitation, any “issuer
free writing prospectus” as defined in Rule 433) or supplement thereto, in light of the circumstances under which they were made)
not misleading to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding
such Holder furnished in writing to the Company by such Holder in the Questionnaire or otherwise expressly for use therein. In no event
shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such
Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.
(c)
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall be permitted to assume the
defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party (whose approval shall not be unreasonably
withheld) and the payment of all fees and expenses incurred in connection with defense thereof; provided, that the failure of
any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this
Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination
is not subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying
Party.
An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to assume the defense of such
Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding (whose approval shall not be
unreasonably withheld); or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified
Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely
to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified
Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party,
the Indemnifying Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying
Party); provided that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of attorneys
at any time for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected
without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior written
consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party,
unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject
matter of such Proceeding.
All
fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating
or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred,
promptly upon receipt of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately determined that an
Indemnified Party is not entitled to indemnification hereunder; provided that the Indemnifying Party may require such Indemnified
Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party
is not entitled to indemnification hereunder).
(d)
Contribution. If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party (by reason of public
policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid
or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of
the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as
well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined
by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact
or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying
Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject
to the limitations set forth in Section 5(c), any reasonable attorneys’ or other reasonable fees or expenses incurred by such party
in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification
provided for in this Section was available to such party in accordance with its terms.
The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to contribute, in the aggregate,
any amount in excess of the amount by which the proceeds actually received by such Holder from the sale of the Registrable Securities
subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have
to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Loan Agreement.
6.
Facilitation of Sales Pursuant to Rule 144. To the extent it shall be required to do so under the Exchange Act, the Company
shall timely file the reports required to be filed by it under the Exchange Act or the Securities Act (including the reports under Sections
13 and 15(d) of the Exchange Act referred to in subparagraph (c)(1) of Rule 144), and shall take such further action as any Holder may
reasonably request, all to the extent required from time to time to enable the Holders to sell Registrable Securities without registration
under the Securities Act within the limitations of the exemption provided by Rule 144. Upon the request of any Holder in connection with
that Holder’s sale pursuant to Rule 144, the Company shall deliver to such Holder a written statement as to whether it has complied
with such requirements.
7.
Miscellaneous.
(a)
Remedies. In the event of a breach by the Company or by a Holder, of any of their obligations under this Agreement, each Holder
or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including
recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company and each Holder agree that
monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions
of this Agreement and further agree that, in the event of any action for specific performance in respect of such breach, it shall waive
the defense that a remedy at law would be adequate.
(b)
Amendments and Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed by the Company
and the Electing Holders. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be
deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or
requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise
of any such right.
(c)
Notices. Except where explicitly stated otherwise, any and all notices or other communications or deliveries required or permitted
to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission,
if such notice or communication is delivered via facsimile or electronic mail as specified in this Section prior to 5:00 p.m. (Eastern
Time) on a Business Day, (ii) the Business Day after the date of transmission, if such notice or communication is delivered via facsimile
or electronic mail as specified in this Agreement later than 5:00 p.m. (Eastern Time) on any date and earlier than 11:59 p.m. (Eastern
Time) on such date, (iii) the Business Day following the date of mailing, if sent by nationally recognized overnight courier service,
or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as follows:
If
to the Company: |
|
TruGolf
Inc. |
|
|
60
N 1400 W |
|
|
Centerville,
UT 84014 |
|
|
Attn:
Brenner Adams |
|
|
Email:
b@trugolf.com |
|
|
|
If
to the Investor: |
|
|
or
such other address as may be designated in writing hereafter, in the same manner, by such Person.
(d)
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (other than by operation of law) its
rights or obligations hereunder without the prior written consent of the Electing Holders. The Investor may not assign their rights and
obligations hereunder (other than by operation of law); provided that an Investor may assign its rights and obligations hereunder
to an Affiliate of such Investor. Upon any distribution of the Registrable Securities to the limited partners of an Investor, this Agreement
shall inure to the benefit of and be binding upon such limited partners receiving the Registrable Securities.
(e)
Execution and Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed shall
be deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that any signature
is delivered by facsimile or electronic mail transmission, such signature shall create a valid binding obligation of the party executing
(or on whose behalf such signature is executed) the same with the same force and effect as if such signature delivered by facsimile or
electronic mail transmission were the original thereof.
(f)
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida without regard
to choice of laws or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction.
(g)
Submission to Jurisdiction. Each of the parties to this Agreement irrevocably and unconditionally submits, for itself and its
property, to the exclusive jurisdiction of the courts of the State of Nevada and of the United States District Court of the Southern
District of Florida, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement,
or for the recognition or enforcement of any judgment, and each of the parties hereto irrevocably and unconditionally agrees that all
claims in respect of any such action or proceeding may be heard and determined in such Florida State court or, to the fullest extent
permitted by applicable law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding
shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
(h)
Waiver of Venue. Each of the parties to this Agreement irrevocably and unconditionally waives, to the fullest extent permitted
by applicable law, (i) any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out
of or relating to this Agreement in any court referred to in Section 7(g) and (ii) the defense of an inconvenient forum to the maintenance
of such action or proceeding in any such court.
(i)
Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.
(j)
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their reasonable
efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term,
provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed
the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal,
void or unenforceable.
(l)
Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto pertaining to the subject matter
hereof, and supersedes all other prior agreements and understandings, both written and oral, between the parties, with respect to the
subject matter hereof.
(m)
Headings; Section References. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise
affect the meaning hereof. Unless otherwise stated, references to Sections, Schedules and Exhibits are to the Sections, Schedules and
Exhibits of this Agreement.
[Signature
Pages Follow]
IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.
|
COMPANY |
|
|
|
TRUGOLF, INC. |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
INVESTOR |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
[Signature
Page to the Registration Rights Agreement]
ANNEX
A
PLAN
OF DISTRIBUTION
The
selling securityholders, including their pledgees, donees, transferees, distributees, beneficiaries or other successors in interest,
may from time to time offer some or all of the shares of Common Stock (collectively, “Securities”) covered
by this prospectus. To the extent required, this prospectus may be amended and supplemented from time to time to describe a specific
plan of distribution.
The
selling securityholders will not pay any of the costs, expenses and fees in connection with the registration and sale of the shares covered
by this prospectus, but they will pay any and all underwriting discounts, selling commissions and stock transfer taxes, if any, attributable
to sales of the shares. We will not receive any proceeds from the sale of the shares of our Common Stock covered hereby.
The
selling securityholders may sell the Securities covered by this prospectus from time to time, and may also decide not to sell all or
any of the Securities that they are allowed to sell under this prospectus. The selling securityholders will act independently of us in
making decisions regarding the timing, manner and size of each sale. These dispositions may be at fixed prices, at market prices prevailing
at the time of sale, at prices related to such prevailing market prices, at varying prices determined at the time of sale, or at privately
negotiated prices. Sales may be made by the selling securityholders in one or more types of transactions, which may include:
|
● |
purchases
by underwriters, dealers and agents who may receive compensation in the form of underwriting discounts, concessions or commissions
from the selling securityholders and/or the purchasers of the Securities for whom they may act as agent; |
|
|
|
|
● |
one
or more block transactions, including transactions in which the broker or dealer so engaged will attempt to sell the Securities as
agent but may position and resell a portion of the block as principal to facilitate the transaction, or in crosses, in which the
same broker acts as an agent on both sides of the trade; |
|
|
|
|
● |
ordinary
brokerage transactions or transactions in which a broker solicits purchases; |
|
|
|
|
● |
purchases
by a broker-dealer or market maker, as principal, and resale by the broker-dealer for its account; |
|
|
|
|
● |
the
pledge of Securities for any loan or obligation, including pledges to brokers or dealers who may from time to time effect distributions
of Securities; |
|
|
|
|
● |
short
sales or transactions to cover short sales relating to the Securities; |
|
|
|
|
● |
one
or more exchanges or over the counter market transactions; |
|
|
|
|
● |
through
distribution by a selling securityholder or its successor in interest to its members, general or limited partners or shareholders
(or their respective members, general or limited partners or shareholders); |
|
|
|
|
● |
privately
negotiated transactions; |
|
|
|
|
● |
the
writing of options, whether the options are listed on an options exchange or otherwise; |
|
|
|
|
● |
distributions
to creditors and equity holders of the selling securityholders; and |
|
|
|
|
● |
any
combination of the foregoing, or any other available means allowable under applicable law. |
A
selling securityholder may also resell all or a portion of its Securities in open market transactions in reliance upon Rule 144 under
the Securities Act provided it meets the criteria and conforms to the requirements of Rule 144.
The
selling securityholders may enter into sale, forward sale and derivative transactions with third parties, or may sell securities not
covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates,
in connection with those sale, forward sale or derivative transactions, the third parties may sell securities covered by this prospectus
and the applicable prospectus supplement, including in short sale transactions and by issuing securities that are not covered by this
prospectus but are exchangeable for or represent beneficial interests in the Common Stock. The third parties also may use shares received
under those sale, forward sale or derivative arrangements or shares pledged by the selling securityholder or borrowed from the selling
securityholders or others to settle such third-party sales or to close out any related open borrowings of Common Stock. The third parties
may deliver this prospectus in connection with any such transactions. Any third party in such sale transactions will be an underwriter
and will be identified in the applicable prospectus supplement (or a post-effective amendment to the registration statement of which
this prospectus is a part).
In
addition, the selling securityholders may engage in hedging transactions with broker-dealers in connection with distributions of Securities
or otherwise. In those transactions, broker-dealers may engage in short sales of securities in the course of hedging the positions they
assume with selling securityholders. The selling securityholders may also sell securities short and redeliver securities to close out
such short positions. The selling securityholders may also enter into option or other transactions with broker-dealers which require
the delivery of securities to the broker-dealer. The broker-dealer may then resell or otherwise transfer such securities pursuant to
this prospectus. The selling securityholders also may loan or pledge shares, and the borrower or pledgee may sell or otherwise transfer
the Securities so loaned or pledged pursuant to this prospectus. Such borrower or pledgee also may transfer those Securities to investors
in our securities or the selling securityholders’ securities or in connection with the offering of other securities not covered
by this prospectus.
To
the extent necessary, we may amend or supplement this prospectus from time to time to describe a specific plan of distribution. We will
file a supplement to this prospectus, if required, upon being notified by the selling securityholders that any material arrangement has
been entered into with a broker-dealer for the sale of shares through a block trade, offering or a purchase by a broker or dealer. The
applicable prospectus supplement will set forth the specific terms of the offering of securities, including:
|
● |
the
number of Securities offered; |
|
|
|
|
● |
the
price of such Securities; |
|
|
|
|
● |
the
proceeds to the selling securityholders from the sale of such Securities; |
|
|
|
|
● |
the
names of the underwriters or agents, if any; |
|
|
|
|
● |
any
underwriting discounts, agency fees or other compensation to underwriters or agents; and |
|
|
|
|
● |
any
discounts or concessions allowed or paid to dealers. |
The
selling securityholders may, or may authorize underwriters, dealers and agents to, solicit offers from specified institutions to purchase
Securities from the selling securityholders at the public offering price listed in the applicable prospectus supplement. These sales
may be made under “delayed delivery contracts” or other purchase contracts that provide for payment and delivery on a specified
future date. Any contracts like this will be described in and be subject to the conditions listed in the applicable prospectus supplement.
Broker-dealers
or agents may receive compensation in the form of commissions, discounts or concessions from the selling securityholders. Broker-dealers
or agents may also receive compensation from the purchasers of Securities for whom they act as agents or to whom they sell as principals,
or both. Compensation as to a particular broker-dealer might be in excess of customary commissions and will be in amounts to be negotiated
in connection with transactions involving securities. In effecting sales, broker-dealers engaged by the selling securityholders may arrange
for other broker-dealers to participate in the resales.
In
connection with sales of Securities covered hereby, the selling securityholders and any underwriter, broker-dealer or agent and any other
participating broker-dealer that executes sales for the selling securityholders may be deemed to be an “underwriter” within
the meaning of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, any profits realized
by the selling securityholders and any compensation earned by such underwriter, broker-dealer or agent may be deemed to be underwriting
discounts and commissions. Because the selling securityholders may be deemed to be “underwriters” under the Securities Act,
the selling securityholders must deliver this prospectus and any prospectus supplement in the manner required by the Securities Act.
This prospectus delivery requirement may be satisfied through the facilities of the NASDAQ Capital Market or NASDAQ Global Market in
accordance with Rule 153 under the Securities Act.
We
and the selling securityholders have agreed to indemnify each other against certain liabilities, including liabilities under the Securities
Act. In addition, we or the selling securityholders may agree to indemnify any underwriters, broker-dealers and agents against or contribute
to any payments the underwriters, broker-dealers or agents may be required to make with respect to, civil liabilities, including liabilities
under the Securities Act. Underwriters, broker-dealers and agents and their affiliates are permitted to be customers of, engage in transactions
with, or perform services for us and our affiliates or the selling securityholders or their affiliates in the ordinary course of business.
The
selling securityholders will be subject to applicable provisions of Regulation M of the Securities Exchange Act of 1934 and the rules
and regulations thereunder, which provisions may limit the timing of purchases and sales of any of the Securities by the selling securityholders.
Regulation M may also restrict the ability of any person engaged in the distribution of the Securities to engage in market-making activities
with respect to the Securities. These restrictions may affect the marketability of such Securities.
In
order to comply with applicable securities laws of some states, the Securities may be sold in those jurisdictions only through registered
or licensed brokers or dealers. In addition, in certain states the Securities may not be sold unless they have been registered or qualified
for sale in the applicable state or an exemption from the registration or qualification requirements is available. In addition, any Securities
of a selling securityholder covered by this prospectus that qualify for sale pursuant to Rule 144 under the Securities Act may be sold
in open market transactions under Rule 144 rather than pursuant to this prospectus.
In
connection with an offering of Securities under this prospectus, the underwriters may purchase and sell securities in the open market.
These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales
involve the sale by the underwriters of a greater number of securities than they are required to purchase in an offering. Stabilizing
transactions consist of certain bids or purchases made for the purpose of preventing or retarding a decline in the market price of the
securities while an offering is in progress.
The
underwriters also may impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting
discount received by it because the underwriters have repurchased securities sold by or for the account of that underwriter in stabilizing
or short-covering transactions.
These
activities by the underwriters may stabilize, maintain or otherwise affect the market price of the Securities offered under this prospectus.
As a result, the price of the Securities may be higher than the price that otherwise might exist in the open market. If these activities
are commenced, they may be discontinued by the underwriters at any time. These transactions may be effected on the NASDAQ Capital Market
or another securities exchange or automated quotation system, or in the over-the-counter market or otherwise.
EXHIBIT
A
FORM
OF
SELLING
SECURITYHOLDER QUESTIONNAIRE
Reference
is made to that certain registration rights agreement (the “Registration Rights Agreement”), dated as of ____________
[●], 2023, by and among by and among TruGolf, Inc.., a Delaware corporation (the “Company”) and Greentree
Financial Group Inc., a Florida corporation (the “Investor”). Capitalized terms used and not defined herein
shall have the meanings given to such terms in the Registration Rights Agreement.
The
undersigned Holder (the “Selling Securityholder”) of the Registrable Securities is providing this Selling Securityholder
Questionnaire pursuant to Section 3(k) of the Registration Rights Agreement. The Selling Securityholder, by signing and returning this
Selling Securityholder Questionnaire, understands that it will be bound by the terms and conditions of this Selling Securityholder Questionnaire
and the Registration Rights Agreement. The Selling Securityholder hereby acknowledges its indemnity obligations pursuant to Section 5(b)
of the Registration Rights Agreement.
The
Selling Securityholder provides the following information to the Company and represents and warrants that such information is accurate
and complete:
(1) |
(a) |
Full
Legal Name of Selling Securityholder: |
|
|
|
|
|
|
|
|
|
|
|
|
|
(b) |
Full
Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities listed in (3) below are held: |
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) |
Full
Legal Name of DTC Participant (if applicable and if not the same as (b) above) through which Registrable Securities listed in (3)
below are held: |
|
|
|
|
|
|
|
|
(2) |
Address
for Notices to Selling Securityholder: |
Telephone
(including area code): |
|
|
Fax
(including area code): |
|
|
(3)
Beneficial Ownership of Registrable Securities:
(a)
Type and Principal Amount/Number of Registrable Securities beneficially owned:
(b)
CUSIP No(s). of such Registrable Securities beneficially owned:
(4) |
Beneficial
Ownership of Other Securities of the Company Owned by the Selling Securityholder: |
Except
as set forth below in this Item (4), the Selling Securityholder is not the beneficial or registered owner of any securities of the Company
other than the Registrable Securities listed above in Item (3).
|
(a) |
Type
and Amount of Other Securities beneficially owned by the Selling Securityholder: |
|
(b) |
CUSIP
No(s). of such Other Securities beneficially owned: |
(5) |
Relationship
with the Company: |
Except
as set forth below, neither the Selling Securityholder nor any of its affiliates, officers, directors or principal equity holders (5%
or more) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates)
during the past three years.
State
any exceptions here:
(6) |
Is
the Selling Securityholder a registered broker-dealer? |
If
“Yes”, please answer subsection (a) and subsection (b):
(a)
Did the Selling Securityholder acquire the Registrable Securities as compensation for underwriting/broker-dealer activities to the Company?
(b)
If you answered “No” to question 6(a), please explain your reason for acquiring the Registrable Securities:
(7) |
Is
the Selling Securityholder an affiliate of a registered broker-dealer? |
If
“Yes”, please identify the registered broker-dealer(s), describe the nature of the affiliation(s) and answer subsection (a)
and subsection (b):
(a)
Did the Selling Securityholder purchase the Registrable Securities in the ordinary course of business (if no, please explain)?
Explain:
(b)
Did the Selling Securityholder have an agreement or understanding, directly or indirectly, with any person to distribute the Registrable
Securities at the same time the Registrable Securities were originally purchased (if yes, please explain)?
Explain:
(8) |
Is
the Selling Securityholder a non-public entity? |
If
“Yes”, please answer subsection (a):
(a)
Identify the natural person or persons that have voting or investment control over the Registrable Securities that the non-public entity
owns:
(9) |
Plan of Distribution: |
The
Selling Securityholder (including its donees and pledgees) intends to distribute the Registrable Securities listed above in Item (3)
pursuant to the Registration Statement in accordance with the Plan of Distribution attached as Annex A to the Registration Rights Agreement.
The
Selling Securityholder acknowledges that it understands its obligations to comply with the provisions of the Securities Exchange Act
of 1934, as amended, and the rules thereunder relating to stock manipulation, particularly Regulation M thereunder (or any successor
rules or regulations), in connection with any offering of Registrable Securities pursuant to the Shelf Registration Agreement. The Selling
Securityholder agrees that neither it nor any person acting on its behalf will engage in any transaction in violation of such provisions.
Pursuant
to the Registration Rights Agreement, the Company has agreed under certain circumstances to indemnify the Selling Securityholder against
certain liabilities.
In
the event the Selling Securityholder transfers all or any portion of the Registrable Securities listed in Item (3) above after the date
on which such information is provided to the Company other than pursuant to the Registration Statement, the Selling Securityholder agrees
to notify the transferee(s) at the time of the transfer of its rights and obligations under this Selling Securityholder Questionnaire
and the Registration Rights Agreement.
In
accordance with the Selling Securityholder’s obligation under the Registration Rights Agreement to provide such information as
may be required by law or by the staff of the Commission for inclusion in the Registration Statement, the Selling Securityholder agrees
to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the date
hereof at anytime while the Registration Statement remains effective. All notices to the Selling Securityholder pursuant to the Registration
Rights Agreement shall be made in writing, by hand-delivery, first-class mail, or air courier guaranteeing overnight delivery to the
address set forth below.
By
signing below, the Selling Securityholder consents to the disclosure of the information contained herein in its answers to Items (1)
through (9) above and the inclusion of such information in the Registration Statement and the related Prospectus. The undersigned understands
that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement
and the related Prospectus.
By
signing below, the undersigned agrees that if the Company notifies the undersigned that the Registration Statement is not available pursuant
to the terms of the Registration Rights Agreement, the undersigned will suspend use of the Prospectus until notice from the Company that
the Prospectus is again available.
Once
this Selling Securityholder Questionnaire is executed by the undersigned and received by the Company, the terms of this Selling Securityholder
Questionnaire, and the representations, warranties and agreements contained herein, shall be binding on, shall inure to the benefit of
and shall be enforceable by the respective successors, heirs, personal representatives, and assigns of the Company and the undersigned
with respect to the Registrable Securities beneficially owned by the undersigned and listed in Item (3) above. This Selling Securityholder
Questionnaire shall be governed by and construed in accordance with the laws of the State of Florida without regard to choice of laws
or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction.
IN
WITNESS WHEREOF, the undersigned, by authority duly given, has caused this Selling Securityholder Questionnaire to be executed and delivered
either in person or by its duly authorized agent.
|
|
|
Beneficial
Owner |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
PLEASE
RETURN THE COMPLETED AND EXECUTED
SELLING
SECURITYHOLDER QUESTIONNAIRE TO THE COMPANY AT:
Exhibit
10.4
Convertible
Promissory Note
THIS
SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE
SOLD OR TRANSFERRED WITHOUT COMPLIANCE WITH THE REGISTRATION OR QUALIFICATION PROVISIONS OF APPLICABLE FEDERAL AND STATE SECURITIES LAWS
OR APPLICABLE EXEMPTIONS THEREFROM.
THE
HOLDER HEREOF SHOULD CONTACT THE RESPONSIBLE OFFICER OF THE ISSUER AT THE ISSUER’S PRINCIPAL OFFICE, CURRENTLY 60 N 1400 W, CENTERVILLE,
UT 84014, TO OBTAIN THE INFORMATION RELATED TO THIS NOTE’S ORIGINAL ISSUE DISCOUNT CALCULATIONS. THIS LEGEND IS INTENDED TO SATISFY
THE ORIGINAL ISSUE DISCOUNT REPORTING REQUIREMENTS UNDER TREASURY REGULATIONS SECTION 1.1275-3.
FOR
VALUE RECEIVED, TruGolf, Inc., a Delaware corporation (the “Issuer”), hereby unconditionally, promises to pay
to (“Holder”) at the office of the Holder , or at such other place as Holder may from time to time designate in writing
to Issuer, in lawful money of the United States of America and in immediately available funds, the principal sum of _________ Dollars
($__________). This Convertible Promissory Note (this “Note”) is issued in accordance with the provisions of that
certain Loan Agreement dated as of the date hereof, among the Issuer and Holder (as amended, restated, supplemented or otherwise modified
from time to time, the “Loan Agreement”) and is entitled to the benefits of the Loan Agreement and the other Transaction
Documents, and reference is hereby made to the Loan Agreement for a statement of the terms and conditions under which the Note evidenced
hereby is required to be repaid. All capitalized terms used herein (which are not otherwise specifically defined herein) shall be used
in this Note as defined in the Loan Agreement.
The
outstanding principal balance of the portion of the Note evidenced by this Note shall be due and payable as provided for in the Loan
Agreement.
Section
1. Definitions.
“Beneficial
Ownership Limitation” shall have the meaning set forth in Section 3(d).
“Buy-In”
shall have the meaning set forth in Section 3(c)v.
“Common
Stock” means the shares of the Company’s Class A common stock, par value $0.0001.
“Conversion”
shall have the meaning ascribed to such term in Section 3(a).
“Conversion
Date” shall have the meaning set forth in Section 3(a).
“Conversion
Price” shall have the meaning set forth in Section 3(b).
“Conversion
Shares” means, collectively, the Common Stock issuable upon conversion of this Note in accordance with the terms hereof.
“Note
Register” shall have the meaning set forth in Section 2(c).
“Equity
Conditions” means, on each of the days during the period in question, (a) the Issuer shall have duly honored all conversions
and redemptions scheduled to occur or occurring by virtue of one or more Notices of Conversion of the Holder, if any, (b) the Issuer
shall have paid all liquidated damages and other amounts owing to the Holder in respect of this Note, (c)(i) there is an effective Registration
Statement pursuant to which the Holder is permitted to utilize the prospectus thereunder to resell all of the Common Stock issuable pursuant
to the Transaction Documents (and the Issuer believes, in good faith, that such effectiveness will continue uninterrupted for the foreseeable
future) or (ii) all of the Conversion Shares issuable pursuant to this Note (and shares issuable in lieu of cash payments of interest)
may be resold pursuant to Rule 144 without volume or manner-of-sale restrictions or current public information requirements as determined
by counsel to the Issuer, (d) the Common Stock is trading on a Trading Market and all of the shares issuable pursuant to the Transaction
Documents are listed or quoted for trading on such Trading Market (and the Issuer believes, in good faith, that trading of the Common
Stock on a Trading Market will continue uninterrupted for the foreseeable future), (e) there is a sufficient number of authorized but
unissued and otherwise unreserved Common Stock for the issuance of all of the shares then issuable pursuant to the Transaction Documents,
(f) there is no existing Event of Default and no existing event which, with the passage of time or the giving of notice, would constitute
an Event of Default, (g) the issuance of the shares in question to the Holder would not violate the limitations set forth in Section
3(d) herein, (h) there has been no public announcement of a pending or proposed Fundamental Transaction or Change of Control Transaction
that has not been consummated and (i) the applicable Holder is not in possession of any information provided by the Issuer, any of its
Subsidiaries, or any of their officers, directors, employees, agents or Affiliates, that constitutes, or may constitute, material non-public
information.
“Exempt
Issuance” means the issuance of (a) Common Stock, options or other equity awards to employees, officers or directors of the
Issuer pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of
Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to
the Issuer, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities
exercisable or exchangeable for or convertible into Common Stock issued and outstanding on the date of this Agreement, provided that
such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend
the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the
disinterested directors of the Issuer, provided that any such issuance shall only be to a Person (or to the equityholders of a Person)
which is, itself or through its subsidiaries, an operating Issuer or an owner of an asset and shall provide to the Issuer additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Issuer is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.
“Fundamental
Transaction” shall have the meaning set forth in Section 4(b).
“Interest
Conversion Rate” means 90% of the lowest VWAP for the 5 consecutive Trading Days ending on the Trading Day that is immediately
prior to the date on which interest is paid in Common Stock (adjusted for share splits, share dividends or similar events).
“Interest
Conversion Shares” shall have the meaning set forth in Section 2(a).
“Interest
Notice Period” shall have the meaning set forth in Section 2(a).
“Interest
Payment Date” shall have the meaning set forth in Section 2(a).
“Interest
Share Amount” shall have the meaning set forth in Section 2(a).
“Issue
Date” means the date first identified in this Note.
“Make-Whole
Amount” shall have the meaning set forth in Section 3(c)(i).
“Notice
of Conversion” shall have the meaning set forth in Section 3(a).
“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
“Registration
Statement” means a registration statement covering the resale of the underlying shares by each Holder.
“Share
Delivery Date” shall have the meaning set forth in Section 3(c)(ii).
“Trading
Day” means a day on which the principal Trading Market is open for trading.
“Trading
Market” means any of the following markets or exchanges on which the Common Stock are listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange (or any successors to any of the foregoing).
“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock are
not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on The Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Issuer,
the fees and expenses of which shall be split by the Issuer and the Purchasers.
Section
2. Interest.
(a)
The Issuer shall pay interest to the Holder on the aggregate unconverted and then outstanding principal amount of this Note at the rate
of 10% per annum, payable quarterly on January 1, April 1, July 1 and October 1, beginning 30 days after the Issue Date, on each Conversion
Date and on the Maturity Date (each such date, an “Interest Payment Date”) (if any Interest Payment Date is not a
Business Day, then the applicable payment shall be due on the next succeeding Business Day), in cash or, at the Holder’s option,
in duly authorized, validly issued, fully paid and non-assessable Common Stock (the “Interest Conversion Shares”)
at the Interest Conversion Rate (the dollar amount to be paid in shares, the “Interest Share Amount”) or a combination
thereof; provided, however, that the Holder may only choose to receive Interest Conversion Shares and payment in Common
Stock may only occur if (i) all of the Equity Conditions have been met (unless waived by the Holder in writing) on the applicable Interest
Payment Date (the “Interest Notice Period”) and through and including the date such Common Stock is actually issued
to the Holder, (ii) the Holder shall have given the Issuer notice in accordance with the notice requirements set forth below (other than
the Make-Whole Amount which shall require notice from the Holder within three (3) Trading Days of a Notice of Conversion), and (iii)
as to any Interest Share Amount, the effective rate of interest shall be calculated at 15% per annum. An interest payment may be deferred
from time to time with the mutual written consent of the parties so long as such consent is made prior to the Interest Payment Date.
The outstanding interest payment shall not accrue further interest during the deferment and such payment shall be due on the following
Interest Payment Date. Notwithstanding the foregoing, the Issuer shall have the ability to elect to pay the interest payments in cash
or in Interest Conversion Shares if the Issuer’s Common Stock’s VWAP is less than $6.00 per share for 5 consecutive Trading
Days ending on the Trading Day that is immediately prior to Interest Payment Date. However, the Issuer may only election to pay in Interest
Conversion Shares if all of the Equity Conditions have been met (unless waived by the Holder in writing). Notwithstanding anything to
the contrary, during any periods that the Note is outstanding and an Event of Default is occurring, the interest rate shall be 15% per
annum for all interest payments paid in cash and 18% per annum for all interest payments paid in stock. Furthermore, except after receiving
Shareholder Approval, neither the Holder nor the Issuer, including any potential aggregation with a third party which is part of a single
plan of financing may utilize its above discretion to receive or issue Interest Conversion Shares if such issuance would exceed the Nasdaq
19.99% Cap.
(b)
Subject to the terms and conditions herein, the decision whether to pay interest hereunder in cash, Common Stock or a combination thereof
shall be at the sole discretion of the Holder. Prior to the commencement of any Interest Notice Period, the Holder shall deliver to the
Issuer a written notice of its election to receive interest hereunder on the applicable Interest Payment Date either in cash, Common
Stock or a combination thereof (other than with respect to any Make-Whole Payment which election shall be made within three (3) Trading
Days of the applicable Conversion Date). During any Interest Notice Period (or after the election is made in connection with a Make-Whole
Payment), the Holder’s election (whether specific to an Interest Payment Date or continuous) shall be irrevocable as to such Interest
Payment Date. Subject to the aforementioned conditions, failure to timely deliver such written notice to the Issuer shall be deemed an
election by the Holder to receive the interest on such Interest Payment Date in cash.
(c)
Interest shall be calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, and shall accrue daily commencing
on the Issue Date until payment in full of the outstanding principal, together with all accrued and unpaid interest, liquidated damages
and other amounts which may become due hereunder, has been made. Payment of interest in Common Stock (other than the Interest Conversion
Shares issued prior to an Interest Notice Period) shall otherwise occur pursuant to Section 3 herein and, solely for purposes of the
payment of interest in shares, the Interest Payment Date shall be deemed the Conversion Date. Interest shall cease to accrue with respect
to any principal amount converted, provided that, the Issuer actually delivers the Conversion Shares within the time period required
by Section 3(c) herein. Interest hereunder will be paid to the Person in whose name this Note is registered on the records of the Issuer
regarding registration and transfers of this Note (the “Note Register”). Except as otherwise provided herein, if at
any time the Issuer pays interest partially in cash and partially in Common Stock to the holders of the Note, then such payment of cash
shall be distributed ratably among the holders of the then-outstanding Notes based on their (or their predecessor’s) initial purchases
of Notes pursuant to the Loan Agreement.
(d)
All overdue accrued and unpaid interest to be paid hereunder shall entail a late fee at an interest rate equal to the lesser of 18% per
annum or the maximum rate permitted by applicable law (the “Late Fees”) which shall accrue daily from the date such
interest is due hereunder through and including the date of actual payment in full. Notwithstanding anything to the contrary contained
herein, if, on any Interest Payment Date the Holder has elected to pay accrued interest in the form of Common Stock but the Issuer is
not permitted to pay accrued interest in Common Stock because it fails to satisfy the conditions for payment in Common Stock set forth
in Section 2(a) herein, then, at the option of the Holder, the Issuer, in lieu of delivering either Common Stock pursuant to this Section
2 or paying the regularly scheduled interest payment in cash, shall deliver, within three (3) Trading Days of each applicable Interest
Payment Date, an amount in cash equal to the product of (x) the number of Common Stock otherwise deliverable to the Holder in connection
with the payment of interest due on such Interest Payment Date multiplied by (y) the lowest VWAP during the period commencing on the
Interest Payment Date and ending on the Trading Day prior to the date such payment is actually made
Section
3. Conversion.
(a)
Voluntary Conversion. Subject to the Nasdaq 19.99% Cap except after Shareholder Approval, at any time after the date that hereof
until this Note is no longer outstanding, this Note shall be convertible, in whole or in part, into Common Stock at the option of the
Holder, at any time and from time to time (subject to the conversion limitations set forth in Section 3(d) hereof) (each a “Conversion”).
The Holder shall effect conversions by delivering to the Issuer a Notice of Conversion, the form of which is attached hereto as Annex
A (each, a “Notice of Conversion”), specifying therein the principal amount of this Note to be converted, the
Make-Whole Amount (as defined below) and the date on which such conversion shall be effected (such date, the “Conversion Date”).
If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion is
deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type
of guarantee or notarization) of any Notice of Conversion form be required. To effect conversions hereunder, the Holder shall not be
required to physically surrender this Note to the Issuer unless the entire principal amount of this Note, plus all accrued and unpaid
interest thereon, has been so converted in which case the Holder shall surrender this Note as promptly as is reasonably practicable after
such conversion without delaying the Issuer’s obligation to deliver the shares on the Share Delivery Date. Conversions hereunder
shall have the effect of lowering the outstanding principal amount of this Note in an amount equal to the applicable conversion. The
Holder and the Issuer shall maintain records showing the principal amount(s) converted and the date of such conversion(s). The Issuer
may deliver an objection to any Notice of Conversion within one (1) Business Day of delivery of such Notice of Conversion. The Holder,
and any assignee by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion
of a portion of this Note, the unpaid and unconverted principal amount of this Note may be less than the amount stated on the face hereof.
(b)
Conversion Price. The conversion price in effect on any Conversion Date shall be equal to $[ ]1, subject to adjustment
herein (the “Conversion Price”).
(c)
Mechanics of Conversion.
i.
Conversion Shares Issuable Upon Conversion of Principal Amount. Subject to the Nasdaq 19.99% Cap, except after Shareholder Approval,
the number of Conversion Shares issuable upon a conversion hereunder shall be determined by the quotient obtained by dividing the outstanding
principal amount of this Note to be converted by (y) the Conversion Price. Additionally, on each Conversion Date, the Company shall pay
to the Holder in duly authorized, validly issued, fully paid and non-assessable Common Stock (the “Make-Whole Shares”)
at the Interest Conversion Rate, or a combination thereof, the sum of (A) all accrued interest on this Note to date plus (B) all interest
that would otherwise accrued on such principal amount of this Note if such converted principal would be held to the Maturity Date (the
amount in clause (B), (the “Make-Whole Amount”). Notwithstanding the foregoing, the Issuer shall have the ability
to elect to pay the Make-Whole Amount in cash or in Make-Whole Shares if the Issuer’s Common Stock’s VWAP is less than $6.00
per share for 5 consecutive Trading Days ending on the Trading Day that is immediately prior to the make-whole payment. Further, should
the issuance of the Make-Whole Shares result in exceeding the Nasdaq 19.99% Cap, except after Shareholder Approval, the Make-Whole Amount
shall be paid in cash.
ii.
Delivery of Conversion Shares Upon Conversion. Not later than two (2) Trading Days after each Conversion Date (the “Share
Delivery Date”), the Issuer shall deliver, or cause to be delivered, to the Holder (A) the Conversion Shares and any Make-Whole
Shares, if applicable, which, on or after the earlier of (i) the six month anniversary of the Issue Date to the extent permitted under
the Securities Act or (ii) the Effectiveness Date (as defined in the Loan Agreement), shall be free of restrictive legends and trading
restrictions (other than those which may then be required by the Loan Agreement) representing the number of Conversion Shares or Make-Whole
Shares, if applicable, being acquired upon the conversion of this Note and (B) a bank check in the amount of accrued and unpaid interest
(if the Holder has elected or if the Issuer is required to pay accrued interest in cash). On or after the earlier of (i) the six-month
anniversary of the Issue Date to the extent permitted under the Securities Act or (ii) the Effectiveness Date, the Issuer shall deliver
any Conversion Shares or Make-Whole Shares, if applicable, required to be delivered by the Issuer under this Section 3 electronically
through the Depository Trust Company or another established clearing corporation performing similar functions.
iii.
Failure to Deliver Conversion Shares. If, in the case of any Notice of Conversion, such Conversion Shares or Make-Whole Shares,
if applicable, are not delivered to or as directed by the applicable Holder by the 3rd Trading Day following the Share Delivery
Date, the Holder shall be entitled to elect by written notice to the Issuer at any time on or before its receipt of such Conversion Shares,
to rescind such Conversion, in which event the Issuer shall promptly return to the Holder any original Note delivered to the Issuer and
the Holder shall promptly return to the Issuer the Conversion Shares or Make-Whole Shares, if applicable, issued to such Holder pursuant
to the rescinded Conversion Notice.
1
[Insert lower of $10 or lowest 10-day VWAP post Business Combination close with a floor price of $5.00]
iv.
Obligation Absolute; Partial Liquidated Damages. The Issuer’s obligations to issue and deliver the Conversion Shares upon
conversion of this Note in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by
the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any
Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged
breach by the Holder or any other Person of any obligation to the Issuer other than the terms hereof, and irrespective of any other circumstance
(other than a violation of law or a violation of the Nasdaq 19.99% Cap) which might otherwise limit such obligation of the Issuer to
the Holder in connection with the issuance of such Conversion Shares; provided, however, that such delivery shall not operate
as a waiver by the Issuer of any such action the Issuer may have against the Holder. In the event the Holder of this Note shall elect
to convert any or all of the outstanding principal amount hereof in accordance with the terms hereof, the Issuer may not refuse conversion
based on any claim that the Holder or anyone associated or affiliated with the Holder has been engaged in any violation of any other
agreement or for any other reason (other than a violation of law), unless an injunction from a court, on notice to Holder, restraining
and or enjoining conversion of all or part of this Note shall have been sought and obtained. In the absence of such injunction, the Issuer
shall issue Conversion Shares or, if applicable, cash, upon a properly noticed conversion.
v.
Compensation for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion. In addition to any other rights available
to the Holder, if the Issuer fails for any reason to deliver to the Holder such Conversion Shares by the 3rd Trading Day following
the Share Delivery Date pursuant to Section 3(c)ii, and if after such 3rd Trading Day following the Share Delivery Date the
Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder’s brokerage firm
otherwise purchases, Common Stock to deliver in satisfaction of a sale by the Holder of the Conversion Shares which the Holder was entitled
to receive upon the conversion relating to such 3rd Trading Day following the Share Delivery Date (a “Buy-In”),
then the Issuer shall (A) pay in cash to the Holder (in addition to any other remedies available to or elected by the Holder) the amount,
if any, by which (x) the Holder’s total purchase price (including any brokerage commissions) for the Common Stock so purchased
exceeds (y) the product of (1) the aggregate number of shares of Common Stock that the Holder was entitled to receive from the conversion
at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed and (B)
at the option of the Holder, either reissue (if surrendered) this Note in a principal amount equal to the principal amount of the attempted
conversion (in which case such conversion shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that
would have been issued if the Issuer had timely complied with its delivery requirements under Section 3(c)ii. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of this Note
with respect to which the actual sale price of the Conversion Shares (including any brokerage commissions) giving rise to such purchase
obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Issuer shall be required to pay the Holder
$1,000. The Holder shall provide the Issuer written notice indicating the amounts payable to the Holder in respect of the Buy-In and,
upon request of the Issuer, evidence of the amount of such loss.
vi.
Reservation of Shares Issuable Upon Conversion. The Issuer covenants that it will at all times reserve and keep available out
of its authorized and unissued Common Stock for the sole purpose of issuance upon conversion of this Note and payment of interest on
this Note (including the Make-Whole Shares), each as herein provided, free from preemptive rights or any other actual contingent purchase
rights of Persons other than the Holder (and the other holders of the Notes), not less than such aggregate number of shares of Common
Stock as shall (subject to the terms and conditions set forth in the Loan Agreement) be issuable (taking into account the adjustments
and restrictions of Section 3(d)) upon the conversion of the then outstanding principal amount of this Note and payment of interest hereunder
(including the Make-Whole Shares) which shall be evidenced by the Company in the TA Instruction Letter in accordance with the terms and
conditions in the Loan Agreement. The Issuer covenants that all Common Stock that shall be so issuable shall, upon issue, be duly authorized,
validly issued, fully paid and nonassessable and, if the Registration Statement is then effective under the Securities Act, shall be
registered for public resale in accordance with such Registration Statement.
vii.
Fractional Shares. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of this Note.
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Issuer shall at its
election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion
Price or round up to the next whole share.
viii.
Transfer Taxes and Expenses. The issuance of Conversion Shares on conversion of this Note shall be made without charge to the
Holder hereof for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion Shares,
provided that the Issuer shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance
and delivery of any such Conversion Shares upon conversion in a name other than that of the Holder of this Note so converted and the
Issuer shall not be required to issue or deliver such Conversion Shares unless or until the Person or Persons requesting the issuance
thereof shall have paid to the Issuer the amount of such tax or shall have established to the satisfaction of the Issuer that such tax
has been paid. The Issuer shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion and all fees
to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic
delivery of the Conversion Shares.
(d)
Holder’s Conversion Limitations. The Issuer shall not effect any conversion of this Note, and a Holder shall not have the
right to convert any portion of this Note, to the extent that after giving effect to the conversion set forth on the applicable Notice
of Conversion, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder
or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)) would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable
upon conversion of this Note with respect to which such determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable upon (i) conversion of the remaining, unconverted principal amount of this Note beneficially owned by the
Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any
other securities of the Issuer subject to a limitation on conversion or exercise analogous to the limitation contained herein (including,
without limitation, any other Notes or the Warrants) beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 3(d), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained
in this Section 3(d) applies, the determination of whether this Note is convertible (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which principal amount of this Note is convertible shall be in the reasonable
discretion of the Holder, and the submission of a Notice of Conversion shall be deemed to be the Holder’s determination of whether
this Note may be converted (in relation to other securities owned by the Holder together with any Affiliates or Attribution Parties)
and which principal amount of this Note is convertible, in each case subject to the Beneficial Ownership Limitation, and the Issuer shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 3(d), in determining the number of outstanding Common Stock, the Holder may rely on the number of outstanding
Common Stock as reflected in (A) the Issuer’s most recent periodic or annual report filed with the Commission, as the case may
be, (B) a more recent public announcement by the Issuer, or (C) a more recent written notice by the Issuer or the Issuer’s transfer
agent setting forth the number of shares Common Stock outstanding. Upon the written or oral request of a Holder, the Issuer shall within
two (2) Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Issuer,
including this Note, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was
reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of Common Stock issuable upon conversion of this Note. The Beneficial Ownership Limitation
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 3(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The
limitations contained in this paragraph shall apply to a successor holder of this Note.
(e)
Transfer Restriction. Notwithstanding anything to the contrary in this Note, until the date that is six (6) months after the date
hereof, the Common Stock issued upon conversion of this Note may not be directly or indirectly transferred, pledged, sold or otherwise
disposed of without the prior written consent of the Issuer (which written consent shall not be unreasonably withheld).
Section
4. Certain Adjustments.
(a)
Stock Dividends and Stock Splits. If the Issuer, at any time while this Note is outstanding: (i) pays a share dividend or otherwise
makes a distribution or distributions payable in shares of Common Stock on Common Stock or any Common Stock Equivalents (which, for avoidance
of doubt, shall not include any Common Stock issued by the Issuer upon conversion of, or payment of interest on, the Notes), (ii) subdivides
outstanding Common Stock into a larger number of shares, (iii) combines (including by way of a reverse share split) outstanding Common
Stock into a smaller number of shares or (iv) issues, in the event of a reclassification of Common Stock, any shares of capital stock
of the Issuer, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of Common Stock
(excluding any treasury shares of the Issuer) outstanding immediately before such event, and of which the denominator shall be the number
of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.
(b)
Fundamental Transaction. If, at any time while this Note is outstanding, (i) the Issuer, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Issuer with or into another Person, (ii) the Issuer (and all of its Subsidiaries,
taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Issuer or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of more than 50%
of the outstanding Common Stock, (iv) the Issuer, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Issuer, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding
Common Stock (not including any Common Stock held by the other Person or other Persons making or party to, or associated or affiliated
with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental
Transaction”), then, upon any subsequent conversion of this Note, the Holder shall have the right to receive, for each Conversion
Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without
regard to any limitation in Section 3(d) on the conversion of this Note), the consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Note is convertible
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 3(d) on the conversion of this Note).
For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one (1) share of Common Stock in such Fundamental
Transaction, and the Issuer shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to
the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the
Alternate Consideration it receives upon any conversion of this Note following such Fundamental Transaction.
(c)
Anti-Dilution Adjustments to Conversion Price. If the Company or any subsidiary thereof, as applicable, at any time while this
Note is outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue
(or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or securities entitling any person
or entity to acquire shares of Common Stock (upon conversion, exercise or otherwise), at an effective price per share less than the then
Conversion Price (such lower price, the “Base Share Price” and such issuances collectively, a “Dilutive Issuance”)
(if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments,
reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which
are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share which is less
than the Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive
Issuance), then the Conversion Price shall be reduced at the option of the Holder and only reduced to equal the Base Share Price. Such
adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. For an avoidance of doubt, Conversion Price
under this Section 4(c) shall not be subject to a floor price and shall adjust in accordance with this section upon a Dilutive Issuance.
The Company shall notify the Holder in writing, no later than two (2) Trading Days following the issuance of any shares of Common Stock
or Common Stock Equivalents subject to this Section 4(c), indicating therein the applicable issuance price, or applicable reset price,
exchange price, conversion price and other pricing terms (such notice the “Dilutive Issuance Notice”). For purposes of clarification,
whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 4(c), upon the occurrence of any Dilutive Issuance,
after the date of such Dilutive Issuance the Holder is entitled to receive a number of Conversion Shares based upon the Base Share Price
regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Conversion. The foregoing shall not apply
to any Exempt Issuance.
(d)
Calculations. All calculations under this Section 4 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 4, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Issuer) issued and outstanding.
(e)
Notice to the Holder.
i.
Adjustment to Conversion Price. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 4, the Issuer
shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.
ii.
Notice to Allow Conversion by Holder. If (A) the Issuer shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Issuer shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Issuer shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Issuer shall be required in connection with
any reclassification of the Common Stock (excluding any events set forth in Section 4(a) above), any consolidation or merger to which
the Issuer (and all of its Subsidiaries, taken as a whole) is a party, any sale or transfer of all or substantially all of the assets
of the Issuer, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (E)
the Issuer shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Issuer, then, in
each case, the Issuer shall cause to be filed at each office or agency maintained for the purpose of conversion of this Note, and shall
cause to be delivered to the Holder at its last address as it shall appear upon the Note Register, at least fifteen (15) calendar days
prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which
the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice. The Holder shall remain entitled to convert this Note during
the 15-day period commencing on the date of such notice through the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.
Section
5. Certain Covenants.
(a)
Distributions on Capital Stock. So long as the Issuer shall have any obligation under this Note, the Issuer shall not without
the Holder’s written consent (a) pay, declare or set apart for such payment, any dividend or other distribution (whether in cash,
property or other securities) on shares of capital stock other than dividends on shares of Common Stock solely in the form of additional
shares of Common Stock or (b) directly or indirectly or through any subsidiary make any other payment or distribution in respect of its
capital stock except for distributions pursuant to any shareholders’ rights plan which is approved by a majority of the Issuer’s
disinterested directors.
(b)
Restrictions on Stock Repurchases. So long as the Issuer shall have any obligation under this Note, the Issuer shall not without
the Holder’s written consent redeem, repurchase or otherwise acquire (whether for cash or in exchange for property or other securities
or otherwise) in any one transaction or series of related transactions any shares of capital stock of the Issuer or any warrants, rights
or options to purchase or acquire any such shares.
(c)
Reserved.
(d)
Sale of Assets. So long as the Issuer shall have any obligation under this Note, the Issuer shall not, without the Holder’s
written consent, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any
consent to the disposition of any assets shall be conditioned on a specified use of the proceeds towards the repayment of this Note.
(e)
Advances and Loans. So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the Holder’s
written consent, lend money, give credit or make advances to any person, firm, joint venture or corporation, including, without limitation,
officers, directors, employees, subsidiaries and affiliates of the Borrower, except loans, credits or advances (a) in existence or committed
on the date hereof and which the Borrower has informed Holder in writing prior to the date hereof, (b) made in the ordinary course of
business or (c) not in excess of $100,000
(f)
Section 3(a)(9) or 3(a)(10) Transaction. So long as this Note is outstanding, the Issuer shall not enter into any transaction
or arrangement structured in accordance with, based upon, or related or pursuant to, in whole or in part, either Section 3(a)(9) of the
Securities Act (a “3(a)(9) Transaction”) or Section 3(a)(l0) of the Securities Act (a “3(a)(l0) Transaction”).
In the event that the Issuer does enter into, or makes any issuance of Common Stock related to a 3(a)(9) Transaction or a 3(a)(l0) Transaction
while this Note is outstanding, a liquidated damages charge of 10% of the outstanding principal balance of this Note, and will become
immediately due and payable to the Holder at its election in the form of cash payment or addition to the balance of this Note.
(g)
Non-Circumvention. The Borrower hereby covenants and agrees that the Borrower will not, by amendment of its Certificate or Articles
of Incorporation or Bylaws, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Note, and will at all times in good faith carry out all the provisions of this Note and take all action as may be required to
protect the rights of the Holder.
Section
6. Registration Rights. In accordance with the terms and conditions of the Loan Agreement, the Company and the Holder shall execute
the Registration Rights Agreement.
Section
7. Miscellaneous.
(a)
Failure or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative
to, and not exclusive of, any rights or remedies otherwise available.
(b)
Amendments. This Note and any provision hereof may only be amended by an instrument in writing signed by the Issuer and the Holder.
The term “Note” and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other
Notes issued pursuant to the Loan Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.
(c)
Presentment. Presentment, demand, protest and notice of presentment, demand, nonpayment and protest are each hereby waived by
the Issuer.
(d)
Governing Law. THIS NOTE SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF NEVADA, WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES. Whenever possible each provision of this Note shall be interpreted in such
manner as to be effective and valid under applicable law, but in case any provision of or obligation under this Note shall be invalid,
illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or
of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.
(e)
Submission to Jurisdiction. Each of the parties to this Agreement irrevocably and unconditionally submits, for itself and its
property, to the exclusive jurisdiction of the courts of the State of Florida and of the United States District Court of the Southern
District of Florida, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement,
or for the recognition or enforcement of any judgment, and each of the parties hereto irrevocably and unconditionally agrees that all
claims in respect of any such action or proceeding may be heard and determined in such Florida State court or, to the fullest extent
permitted by applicable law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding
shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
(f)
Loan Agreement Terms. In addition to and without limitation of any of the foregoing, this Note shall otherwise be subject to all
of general terms and conditions contained in the Loan Agreement, mutatis mutandis.
(g)
Notice of Corporate Events. Except as otherwise provided below, the Holder of this Note shall have no rights as a Holder of Common
Stock unless and only to the extent that it converts this Note into Common Stock. The Issuer shall provide the Holder with prior notification
of any meeting of the Issuer’s shareholders (and copies of proxy materials and other information sent to shareholders). In the
event of any taking by the Issuer of a record of its shareholders for the purpose of determining shareholders who are entitled to receive
payment of any dividend or other distribution, any right to subscribe for, purchase or otherwise acquire (including by way of merger,
consolidation, reclassification or recapitalization) any share of any class or any other securities or property, or to receive any other
right, or for the purpose of determining shareholders who are entitled to vote in connection with any proposed sale, lease or conveyance
of all or substantially all of the assets of the Issuer or any proposed liquidation, dissolution or winding up of the Issuer, the Issuer
shall mail a notice to the Holder, at least twenty (20) days prior to the record date specified therein (or thirty (30) days prior to
the consummation of the transaction or event, whichever is earlier), of the date on which any such record is to be taken for the purpose
of such dividend, distribution, right or other event, and a brief statement regarding the amount and character of such dividend, distribution,
right or other event to the extent known at such time. The Issuer shall make a public announcement of any event requiring notification
to the Holder hereunder substantially simultaneously with the notification to the Holder in accordance with the terms of this Section
7(g) including, but not limited to, name changes, recapitalizations, etc. as soon as possible under the law.
(h)
Usury. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing
usury, the applicable provision shall automatically be revised to equal the maximum rate of interest or other amount deemed interest
permitted under applicable law. The Issuer covenants (to the extent that it may lawfully do so) that it will not seek to claim or take
advantage of any law that would prohibit or forgive the Issuer from paying all or a portion of the principal or interest on this Note.
(i)
Remedies. The Issuer acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder,
by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Issuer acknowledges that the remedy at law
for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Issuer
of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, including
the Liquidated Damages Penalty and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing
or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic
loss and without any bond or other security being required. No provision of this Note shall alter or impair the obligation of the Issuer,
which is absolute and unconditional, to pay the principal of, and interest on, this Note at the time, place, and rate, and in the form,
herein prescribed.
(j)
Severability. In the event that any provision of this Note is invalid or unenforceable under any applicable statute or rule of
law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity
or enforceability of any other provision hereof.
(k)
Binding Effect. Whenever in this Note reference is made to Holder or an Issuer, such reference shall be deemed to include, as
applicable, a reference to their respective successors and assigns. The provisions of this Note shall be binding upon each Issuer and
its successors and assigns, and shall inure to the benefit of Holder and its successors and assigns.
IN
WITNESS WHEREOF, the undersigned have executed this Note the day and year first written above written intending to be legally bound hereby.
ISSUER: |
|
|
|
|
TruGolf,
Inc. |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
HOLDER
Acknowledged
and Agreed:
Signature
Page to Convertible Promissory Note
ANNEX
A
NOTICE
OF CONVERSION
The
undersigned hereby elects to convert principal under the Convertible Promissory Note of TruGolf Inc., a Delaware Corporation (the “Issuer”),
into shares of common stock (the “Common Stock”), of the Issuer according to the conditions hereof, as of the date
written below. If Common Stock is to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer
taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Issuer in
accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.
By
the delivery of this Notice of Conversion the undersigned represents and warrants to the Issuer that its ownership of the Common Stock
does not exceed the amounts specified under Section 3(d) of this Note, as determined in accordance with Section 13(d) of the Exchange
Act.
The
undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer
of the aforesaid Common Stock.
Conversion
calculations:
Date
to Effect Conversion:
Principal
Amount of Note to be Converted:
Payment
of Interest in Common Stock __ yes __ no
If
yes, $_____ of Interest Accrued on Account of Conversion at Issue.
Number
of Common Stock to be issued:
Signature:
Name:
Address
for Delivery of Common Stock Certificates:
Or
DWAC
Instructions:
Broker
No:_________________
Account
No:_________________
v3.23.3
Cover
|
Nov. 02, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 02, 2023
|
Entity File Number |
001-40970
|
Entity Registrant Name |
Deep
Medicine Acquisition Corp.
|
Entity Central Index Key |
0001857086
|
Entity Tax Identification Number |
85-3269086
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
595
Madison Avenue
|
Entity Address, Address Line Two |
12th Floor
|
Entity Address, City or Town |
New
York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10017
|
City Area Code |
(917)
|
Local Phone Number |
289-2776
|
Written Communications |
true
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Class Common Stock Par Value 0. 0001 Per Share [Member] |
|
Title of 12(b) Security |
Class
A Common Stock, par value $0.0001 per share
|
Trading Symbol |
DMAQ
|
Security Exchange Name |
NASDAQ
|
Rights Each Exchangeable Into Onetenth Of One Share Of Class Common Stock [Member] |
|
Title of 12(b) Security |
Rights,
each exchangeable into one-tenth of one share of Class A Common Stock
|
Trading Symbol |
DMAQR
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=DMAQ_ClassCommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=DMAQ_RightsEachExchangeableIntoOnetenthOfOneShareOfClassCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Deep Medicine Acquisition (NASDAQ:DMAQ)
Historical Stock Chart
From Sep 2024 to Oct 2024
Deep Medicine Acquisition (NASDAQ:DMAQ)
Historical Stock Chart
From Oct 2023 to Oct 2024